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ABSTRACT 
 
Pancreatic neuroendocrine tumors (PNETs) are rare but clinically challenging 
neoplasms in which the genetic background was poorly understood until a few years ago. 
Multiple Endocrine Neoplasia type 1 (MEN1) was reported as the most commonly mutated 
gene in both hereditary and sporadic tumors. Several mouse models have been generated 
to follow tumorigenesis of PNETs with alterations of MEN1. With the advent of whole-exome 
sequencing, new insights on the genetics basis of the disease were achieved with the report 
of two novel frequently mutated genes in about 40% of PNETs: Death domain associated 
protein (DAXX) and Alpha thalassemia/mental retardation X-linked (ATRX). PNETs with 
loss of expression of DAXX and ATRX have been correlated with the alternative lengthening 
of telomeres (ALT), an alternative mechanism to telomerase in order to maintain telomere 
length and achieve cell immortalization. These results prompted us to develop a novel 
mouse model of disease with conditional ATRX deletion in the β-cells of the endocrine 
pancreas using the RIP-Cre/LoxP recombination system – an ATRX conditional knockout 
mouse model.  
The main goal of this dissertation was to evaluate and characterize the ATRX 
conditional knockout mouse model. The study started by genotyping the animals of the 
study sample by allele-specific PCR following DNA extraction from FFPE tissues, 
performing the histological evaluation of the pancreas tissue slides, characterization of the 
endocrine cell population and determination of Cre recombination and ATRX expression in 
pancreatic β-cells by immunohistochemistry studies, as well as performing the optimization 
of telomere-specific fluorescence in situ hybridization combined with immunofluorescence 
to localize telomeres in the nuclei of β-cells. 
The study sample was comprised by 161 animals, of which 63 were controls and 98 
were ATRX floxed mice. The histological evaluation of the animals revealed a prominent 
role of inflammation in the mice pancreas. Leukocytic infiltration in the exocrine tissue and 
infiltration in the pancreatic islets (insulitis) were analysed separately and both were 
revealed to be more prevalent in ATRX floxed mice when compared to controls (P > 0.05); 
both types of infiltration were shown with significant differences among age groups, 
progressing as the age of the mice also increased (P < 0.05). Regarding the final score of 
pancreatic lesions, ATRX floxed mice were shown to develop moderate and high-grade 
lesions more frequently (P > 0.05); significant differences were found regarding age groups 
(P < 0.05). The mice of the study sample presented a marked increase of the endocrine 
population, with severely enlarged and irregularly shaped islets. The endocrine fraction did 
not show significant differences among genotype groups (P > 0.05) but it showed a 
 XIII 
progressive increase as the animals age also progressed (P < 0.05). Hyperplasic and 
coalescent islets were shown to maintain a strong pattern of insulin expression, while the 
expression of glucagon is dispersed and in a less extent than expected. About 12% of the 
subjects developed pancreatic tumors that lack staining for the conventional markers of 
neuroendocrine lineage. Cre recombinase was found to be expressed specifically in the 
nuclei of β-cells. ATRX expression was also observed in the nuclei of control, heterozygous 
and homozygous mice. The optimized protocol of telomere-specific FISH combined with 
immunofluorescence allowed the localization of telomeres in the nuclei of pancreatic β-cells. 
Extensive exocrine and endocrine infiltrations, islet hyperplasia and pancreatic 
tumor development were found to be dependent on age, and might play as key factors 
affecting the progression of these pathologies. The characterization of the inflammation 
detected in this study sample, previously undescribed, either for the RIP-Cre strain or any 
mouse model of pancreatic neuroendocrine tumorigenesis, is a novel result that will require 
further investigation. A panel of immunohistochemistry markers will be further adapted to 
assess the neuroendocrine background of tumors, as well as the hypothesized poorly 
differentiated phenotype. Cre recombinase and ATRX expression will be characterized in 
full extent to allow the assessment of the Cre/LoxP system recombination efficiency. These 
were unexpected and interesting findings that report for the first time a unique model of 
ATRX conditional knockout mouse model. 
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RESUMO 
 
Os tumores neuroendócrinos do pâncreas (PNETs) compreendem um grupo de 
neoplasias raras, mas desafiantes do ponto de vista clínico, e cuja composição genética 
era pouco conhecida até recentemente. As mutações do gene da neoplasia endócrina 
múltipla tipo 1 (MEN1) eram reconhecidas como as alterações mais frequentes em tumores 
hereditários, assim como nos esporádicos. Diversos modelos foram desenvolvidos para se 
seguir o processo tumorigénico dos PNETs baseados em alterações no MEN1. A 
sequenciação completa do exoma permitiu a aquisição de novos dados a respeito da base 
genética da doença, nomeadamente ao reportar dois novos genes frequentemente 
mutados em PNETs: DAXX e ATRX. Os PNETs com perda de expressão de DAXX e ATRX 
foram ainda relacionados com o mecanismo alternativo de alongamento dos telómeros 
(ALT), uma alternativa à telomerase para as células manterem os seus telómeros e assim 
poderem aspirar atingir um estado de imortalidade. Estes resultados levaram-nos a 
desenvolver um novo modelo de doença que se baseia na deleção condicional do ATRX 
nas células β-pancreáticas, usando um sistema de recombinação RIP-Cre/LoxP.  
O principal objetivo desta dissertação foi avaliar e caraterizar o modelo de doença 
de remoção do gene ATRX das células β-pancreáticas, um modelo condicional. O estudo 
iniciou-se pela genotipagem dos animais da população em estudo após ter sido extraído 
DNA de tecidos parafinados; seguiu-se a avaliação histológica das lâminas de tecido 
pancreático, assim como a caraterização da população celular endócrina e a determinação 
da recombinação da Cre e consequente expressão de ATRX em células β-pancreáticas 
através de estudos imunohistoquímicos. Foi também realizada a otimização de FISH 
específico para telómeros, combinado com imunofluorescência de modo a localizar 
telómeros nos núcleos de células β. 
A população do estudo revelou ser composta por 161 animais, dos quais 63 são 
controlos e 98 têm sequências loxP a flanquear o ATRX. A avaliação histológica indicou 
um papel proeminente de inflamação nos pâncreas dos animais. As infiltrações leucocíticas 
no tecido exócrino e nas ilhotas pancreáticas (insulite) foram analisadas separadamente, 
e ambas se revelaram mais prevalentes em animais com o ATRX flanqueado quando 
comparado com animais controlo (P > 0.05); ambos os tipos de infiltração demonstraram 
diferenças significativas entre grupos de idade, progredindo à medida que a idade dos 
animais também aumentava (P < 0.05). Em relação à quantificação de lesões pancreáticas, 
os animais com o ATRX flanqueado demonstraram desenvolver lesões moderadas e de 
grau elevado mais frequentemente (P > 0.05); diferenças significativas foram encontradas 
em relação a grupos de idade (P < 0.05). Os murganhos da amostra apresentaram ainda 
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um acentuado incremento na fração endócrina, com ilhotas aumentadas e de forma 
irregular. A fração endócrina não demonstrou diferenças significativas entre grupos de 
genótipo (P > 0.05), mas demonstrou um aumento progressivo à medida que a idade dos 
animais também progrediu (P < 0.05). Ilhotas hiperplásicas e coalescentes demonstraram 
manter um padrão forte de expressão de insulina, enquanto a expressão de glucagon se 
revelou dispersa e numa menor extensão daquela que seria esperada. Cerca de 12% dos 
indivíduos desenvolveram tumores pancreáticos que não apresentam expressão dos 
marcadores convencionais de linhagem neuroendócrina. Foi demonstrada a expressão da 
proteína Cre especificamente nos núcleos de células β. A expressão de ATRX foi também 
observada no núcleo de murganhos controlo, heterozigóticos e homozigóticos. O protocolo 
otimizado de FISH específico para telómeros combinado com imunofluorescência permitiu 
a localização de telómeros nos núcleos de células β pancreáticas.  
A extensa infiltração exócrina e endócrina, hiperplasia de ilhotas e desenvolvimento 
de tumores pancreáticos foram demonstrados ser dependentes da idade, e provavelmente 
participam como fatores chave a afetar a progressão destas patologias. A inflamação 
detetada na amostra, previamente não descrita, quer para a estirpe RIP-Cre, como para 
qualquer um dos modelos animais de tumorigénese em tumores neuroendócrinos 
pancreáticos, é um resultado inovador que requer uma investigação mais detalhada no 
futuro. Um painel de marcadores imunohistoquímicos será adaptado futuramente para 
avaliar o fenótipo neuroendócrino dos tumores, assim como o seu possível fenótipo de 
tumor pouco diferenciado. A expressão de Cre e ATRX será caraterizada em toda a 
população para permitir a avaliação da eficiência da recombinação do sistema Cre/LoxP. 
Estes resultados foram inesperados e interessantes, reportando pela primeira vez um 
modelo animal único para a perda condicional do gene ATRX em células β-pancreáticas.  
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1. INTRODUCTION 
 
 
1.1. The pancreas 
 
The pancreas is a glandular organ of the gastrointestinal system. It is localized in 
the upper abdomen, posteriorly to the stomach and is commonly referred to present 3 main 
compartments, comprising the head (near the duodenum), the body and the tail (that 
represent its extension towards the hilum of the spleen).  
It is composed by two major components with distinct functions: the exocrine and 
endocrine counterparts. The exocrine portion comprehends about 95% of the pancreatic 
mass and it is composed by acinar and duct cells with connective tissue, vessels and 
nerves. Acinar cells are responsible for the production and release of digestive enzymes 
into a series of progressively larger ducts that will end up joining to form the pancreatic duct 
that conducts the products into the duodenum. The endocrine pancreas is composed of 
islets of Langerhans or pancreatic islets, responsible for the production and secretion of 
several hormones into the bloodstream that control metabolism and energy storage. 
Pancreatic islets constitute a minor fraction of the pancreatic mass, around 1-2% of the 
pancreas in adults of most mammalian species [1].  
 
Figure 1. Pancreas tissue stained with hematoxylin and eosin (H&E). 
Representation of pancreas exocrine tissue and an islet of Langerhans (endocrine). 
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Islets of Langerhans are highly-vascularized micro-organs consisting of different 
neuroendocrine cell populations and are members of the diffuse endocrine system. 
Comparative studies of pancreatic islets among different species have determined 
variations in both their composition and architecture [2, 3]. Human islets have an average 
diameter of 50 μM and are composed of specific cells that have the capacity to produce, 
store and secret specific peptide hormones, i.e., β-cells produce insulin (75-80%) which 
occupy the majority of the islet, α-cells are responsible for glucagon (15%), δ-cells for 
somatostatin (5%), and rare γ-cells produce and release pancreatic polypeptide (PP). In 
mice, islets are larger, with an average diameter of 116 μM. They present a well-defined 
structure with a central core of β-cells (60-80%) with the remaining endocrine cells being 
dispersed at the periphery of the islet and in a similar frequency when compared to humans: 
α-cells (15-20%), δ-cells (<10%) and PP-cells (<1%) [2, 4].   
 
Figure 2. Comparison between human and mice Langerhans islets and cell 
population differential peptide hormone expression. A: Human pancreatic islet 
(H&E). B-D: Immunohistochemistry staining for insulin, glucagon and somatostatin, 
respectively, in a human pancreas. E: Mouse islet (H&E). F-I: Staining for insulin, 
glucagon, somatostatin and pancreatic polypeptide, respectively. Adapted with 
permission from Asa et al. (2011) [5] and Wieczorek et al. (1998) [3]. 
 
1.2. Pancreatic neuroendocrine tumors 
 
Pancreatic neuroendocrine tumors (PNETs) are a rare and heterogeneous group of 
tumors, with distinct functional and biological behavior depending on location, tumor size 
and clinical symptoms that pose diagnostic and therapeutic challenges [6-8]. A spectrum of 
these neoplasms can be found in the pancreas, ranging from well-differentiated neoplasms 
to poorly-differentiated carcinomas. They represent less than 3% of all pancreatic tumors 
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with an annual incidence of 1 per 100.000 people. This value increases in autopsy studies, 
which usually identify clinically unrecognizable, asymptomatic and small lesions, resulting 
therefore in a higher incidence [5, 8-10]. A better prognosis and improved long-term survival 
is observed for PNET patients when compared with patients presenting pancreatic 
adenocarcinoma. The overall 5-year survival rate for PNETs is in the range of 30% for 
nonfunctional tumors and up to 97% in insulinomas [8, 11, 12]. However, the prognosis 
worsens substantially in patients presenting poorly differentiated neoplasms or carcinomas 
and most importantly with the presence of metastatic disease.  
Pancreatic neuroendocrine tumors have no significant gender predilection and can 
occur at all ages, with an incidence peak between the third and sixth decade of life [5, 10, 
11, 13]. 
Until a few years ago, PNETs were also called islet cell tumors. However, recent 
evidence suggests two possible origins for these tumors: mature endocrine cells in the 
pancreas (α, β, δ and γ cells) or multipotent stem cells that can differentiate into endocrine 
and exocrine cells in the pancreas [5, 11, 14, 15].  
 
1.2.1. Classification of pancreatic neuroendocrine tumors  
 
During the last decades, the refinement of a classification system for PNETs was 
gained with the increasing interest in these tumors comprehension and with the consequent 
better understanding of these neoplasms. Currently, the classification of PNETs relies 
mainly in four categories to understand the disease: functionality, as “functional or 
nonfunctional”, according to the presence of a clinical syndrome as a consequence of 
inadequate hormone production; tumor biology and morphological features, to determine 
what is the aggressiveness and expected outcome of the tumor/disease; “tumor-node-
metastasis (TNM) classification”, in order to evaluate what is the spread of the disease; and, 
finally, if there is an association with inherited syndromes to determine if we are in the 
presence of “sporadic or syndromic-associated” neoplasm [10]. 
 
1.2.1.1. Functionality 
A clinically functioning PNET gives rise to signs and symptoms of hormone excess. 
The clinical symptoms of functional tumors can include Whipple’s triad, carcinoid syndrome 
and watery diarrhea/hypokalemia/aclorhydria syndrome [9, 15]. There are several types of 
functional tumors according to the hormone they produce that can present specific clinical 
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signs. Insulinomas are the most common functioning PNETs and the secretion of insulin in 
excess results in hypoglycemia; less than 10% of these tumors are malignant [14, 16]. 
Gastrinomas are the second most incident tumors and normally associate with the Zollinger-
Ellison syndrome (ZES). ZES is associated with an excessive secretion of gastric acid 
causing peptic ulcers, gastric esophagus reflux disease and diarrhea. About 60 to 90% of 
gastrinomas have malignant potential, contrarily to what is observed in insulinomas [16]. 
VIPomas, glucagonomas, somatostatinomas (SSomas), growth hormone releasing 
hormone (GRH) tumors (GRHomas), and adrenocorticotropic hormone (ACTH) producing 
tumors (ACTHomas) have been established as rare functioning tumors with high malignant 
potential [7, 16]. VIPomas give rise to a disorder known as pancreatic cholera causing a 
profound and chronic watery diarrhea, as well as severe dehydration. Glucagonomas cause 
a spectrum of features including rashes, glucose intolerance and weight loss. SSomas are 
known to cause diabetes mellitus, cholelithiasis and diarrhea. The main symptoms of 
GRHomas and ACTHomas are acromegaly and Cushing’s syndrome, respectively [7, 16]. 
Other types of functioning tumors are described but their incidence is exceedingly rare. This 
wide variety of hormone-producing tumors reflects the heterogeneity of tumor cell origin.  
Approximately 60% to 90% of PNETs are classified as nonfunctioning since they 
are not associated to a specific hormonal hypersecretion syndrome [16-18]. Although they 
might produce and secrete hormones, their quantity and biological activity may not be 
enough to produce distinct clinical syndromes. These tumors only become clinically 
apparent when they reach a certain size causing a compression effect and/or invading 
adjacent organs or even when they metastasize at distance; they can also be detected 
incidentally when performing abdominal imaging for other reasons [5, 19]. 
 
1.2.1.2. Tumor biology and morphology 
 
The second category of classification is based on the features of tumor biology and 
morphology which has evolved over the years. In 2010, the World Health Organization 
(WHO) released a classification system for PNETs using a proliferation-based grading 
system; the system relies in the mitotic count (per 10 HPF) or in the proliferation 
measurement based on the Ki-67 labelling index. Based on the WHO 2010 classification, 
the tumors were divided in 4 categories: hyperplastic and preoplastic lesions, mixed 
adenoneuroendocrine carcinoma, neuroendocrine tumors (NET) Grade 1 and 2 and 
neuroendocrine carcinomas (NEC) Grade 3. NET G1 comprised less than 2 mitotic counts 
per 10 HPF, with a Ki-67 labeling index of less or equal to 2%. NET G2 included 2-20 mitotic 
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counts per 10 HPF, and 3 to 20% of Ki-67 labeling. NEC G3 was assigned to more than 20 
mitotic counts per 10 HPF and a Ki-67 labeling index of more than 20%. The PNETs 
included in G1 or G2 categories were well-differentiated NET, whereas G3 tumors were 
poorly differentiated NEC, distinguishing additionally the small and large cell subtypes in 
NEC [20].  
A new WHO classification of endocrine tumors was recently released and updated 
the classification system with the introduction of novel features for PNETs. The tumors are 
now divided in 3 main categories: Mixed neuroendocrine-non-neuroendocrine neoplasms 
(MiNEN); NET G1/G2/G3 (well-differentiated neuroendocrine neoplasms, NEN); and NEC 
G3 (poorly differentiated NEN, large or small cell types). Relatively to the 2010 
classification, the Ki-67 index of NET G2 tumors was updated, becoming less than 3% 
(instead of ≤ 2%). An additional Grade 3 sub-category was added to well-differentiated 
neoplasms, with a labelling index of more than 20% and more than 20 mitotic counts per 
10 HPF. NEC G3 (poorly differentiated carcinomas) continue to present a Ki-67 proliferative 
index superior to 20%, as well as more than 20 mitotic counts per 10 HPF [21]. 
 
1.2.1.3. TNM staging system 
 
The evaluation of the extension of the disease is inferred in the tumor-node-
metastasis (TNM) staging system, an important tool for the stratification of patients into 
different stages at diagnosis. The planning of therapeutic approaches is based on this 
staging system, whose success depends on the ability to reflect the biology and natural 
history of the cancer. In 2006, the European Neuroendocrine Tumor Society (ENETS) 
proposed a staging system for PNETs and in 2010, the World Health Organization (WHO), 
Union for International Cancer Control (UICC), and the American Joint Committee for 
Cancer (AJCC) also released an updated system. Both are used nowadays and they are 
predictive of patient outcome, using identical TNM terminologies but referring to slightly 
different extents of disease. According to the ENETS TNM staging system, the 5-year 
survival rate for stage I disease is almost 100%, 93% for stage II, 65% for stage III and 35% 
for stage IV [22]. Using the AJCC/UICC/WHO TNM staging, the 5-year survival rates for 
stages I, II, III and IV are 92%, 84%, 81% and 57%, respectively [12]. There are slight 
discrepancies between the two staging systems: a cohort study of 1072 post-surgical 
PNETs patients proved a superiority of the ENETS system when compared to the 
AJCC/UICC/WHO system for stratifying risk of death and creating risk-based treatment 
guidelines [23]. However, using either system does not appear to have an adverse effect 
on diagnosis and management. 
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1.2.1.4. Association with inherited genetic syndromes 
 
A small fraction, about 10%, of PNETs arise in the context of different inherited 
syndromes: Multiple Endocrine Neoplasia type 1 (MEN1), Von Hippel-Lindau disease 
(VHL), Neurofibromatosis type 1 (NF1) and Tuberous Sclerosis (TSC). The most prevalent 
syndrome is MEN1, in which up to 80% of patients develop PNETs [11, 14, 24]. These 
patients are also predisposed to develop adenomas of the parathyroid and pituitary glands. 
This is an autosomal-dominant condition due to germline mutations in MEN1 tumor 
suppressor gene at chromosome 11q13 which encodes menin, a nuclear protein that 
interacts with many other proteins or transcription factors important for cell growth 
regulation, cell cycle progression and other cellular processes [8, 25, 26]. PNETs 
associated with MEN1 develop at earlier ages when compared to sporadic tumors [5], and 
they display a wide variety of molecular abnormalities, such as chromosomal loss, 
chromosomal loss with duplication, mitotic recombination or point mutation of the wild-type 
allele [5, 24].  
The second most prevalent syndrome is the VHL disease, an autosomal-dominant 
condition in which 10% to 17% of patients develop PNETs [24, 27]. The disease may 
present other types of benign and malignant neoplasms, including retinal angiomas, clear 
cell renal cell carcinomas, phaeochromocytomas, paragangliomas, among others. VHL 
disease is caused by mutations in the VHL tumor suppressor gene on chromosome 3p25 
that encodes for pVHL, an important protein in the regulation of angiogenic growth and the 
activity of various factors such as VEGF, PDGF, TGFα and erythropoietin [5, 8, 25].  
NF1 is an autosomal dominant disorder characterized by the occurrence of 
neurofibromas, central nervous system gliomas, phaeochromocytomas, paragangliomas, 
amongst other manifestations [5, 25]. The disease is caused by mutation in the NF1 gene 
on chromosome 17q11.2 that encodes the protein neurofibromin, which affects cell growth, 
signalling regulated by activation of p21, Ras and through the mTOR pathway. PNETs occur 
in less than 10% of NF1 patients[14, 24].  
TSC is an autosomal dominant disorder, caused by mutations in one of two genes: 
TSC1 gene (which encodes the protein hamartin) or TSC2 gene (which encodes the protein 
tuberin). These two proteins form a dimer important for various cellular processes. PNETs 
have been reported in only a small percentage of TS patients [24]. 
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1.2.2. Histopathology  
 
Pancreatic neuroendocrine tumors are typically well-circumscribed and have 
morphological features that depend on their level of differentiation [11]. Well-differentiated 
PNETs have tumor cells arranged in solid nests surrounded by thin vascular stroma and 
trabecular and/or gland-like formations. Tubuloacinar units and perivascular 
pseudorosettes are also considered specific of these tumors [5, 11, 28]. They present 
characteristic cytological features: round to ovoid cells with eosinophilic and granular 
cytoplasm and a recognizable dispersed chromatin pattern in the nuclei [5, 28]. As for 
poorly-differentiated neuroendocrine carcinomas, they are sub-divided in two groups based 
on cell size: small- and large-cell variants. The large-cell variant has cells with prominent 
nucleoli and variable cytoplasm; on the other hand, the small-cell variant presents cells with 
round, ovoid or spindle-shaped nuclei in which the chromatin is coarse, with high nucleus-
to-cytoplasm ratio and prominent nuclear molding. The large-cell variant presents higher 
cellular atypia [5, 28]. Necrosis is common in both these variants. It is common for poorly-
differentiated neuroendocrine carcinomas to morphologically resemble poorly differentiated 
adenocarcinomas or anaplastic carcinomas of the pancreas [28].  
 
1.2.3.  Immunohistochemistry 
 
PNETs are associated with cell lineage markers responsible for the production of 
cytoplasmic or membrane neuroendocrine granules, which can be highlighted by 
immunohistochemistry. These markers can be used when performing a differential 
diagnosis. A stronger staining pattern is normally obtained for well-differentiated tumors 
when compared to poorly differentiated cases. Chromogranin A (CgA) and synaptohysin 
(SYN) are the most used markers, but others such as the Cluster of Differentiation of neural 
cell adhesion (CD56) and Neuronal Specific Enolase (NSE) are also used [11, 28]. CgA 
belongs to the family of granin glycoproteins, which constitute major components of 
secretory granules of various neuronal and endocrine cells. It constitutes a valuable and 
specific marker of neuroendocrine tumors. It is a vital factor in the diagnosis and monitoring 
of disease, since its serum concentrations correlate with the degree of tumor differentiation, 
hepatic metastization, disease progression and treatment efficacy [29, 30]. Synaptophysin 
is a protein detected in tumors of neuroendocrine differentiation and it has also been 
considered a sensitive but a less specific marker of these tumors [31]. CD56 antibody 
constitutes a less specific neuroendocrine marker, but it is still useful in the differential 
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diagnosis of these tumors [28]. As for NSE, it is an integral membrane glycoprotein of 
neuronal synaptic vesicles; it lacks specificity when compared to CgA or SYN but it can be 
useful when combined with the latter [11, 32].  
 
1.3. Genetic profile of sporadic pancreatic neuroendocrine tumors  
 
About 90% of PNETs arise as sporadic neoplasms. The pathogenesis and genetic 
background of these tumors still lacks understanding but the research concerning the matter 
has been vastly growing over the years.  
Chromosomal gains or losses have been consistently reported in PNETs. Losses in 
chromosomes 1, 3p, 6q, 11q, 17p or 22q were already observed, as well as gains in 
chromosomes 4 or 9q. The most common and well-characterized abnormality identified a 
few years ago was loss of heterozygosity (LOH) at chromosome 11q13, which includes the 
locus of the MEN1 gene; both sporadic and familial PNETs present LOH overlapping this 
region. This genetic event has been identified in sporadic gastrinomas, insulinomas, 
glucagonomas, VIPomas and non-functioning tumors, and reported with an overall 
incidence of approximately 35% [19, 25, 33-35]. The tumor suppressor genes pRb and p53 
were shown to be usually intact in well-differentiated PNETs; however, p53 abnormalities 
are common in poorly differentiated NECs [13, 19]. O6-methylguanine-DNA-
methyltransferase (O6-MGMT) also appears to be downregulated in malignant tumors when 
compared to the benign ones; in contrast, the proto-oncogene MET is up-regulated in the 
malignant cases [25].  
Due to the insufficient information about these tumors either to predict prognosis or 
to develop personalized treatments aiming to improve disease management, it was 
necessary to gain a deeper insight into the genetic basis of PNETs. In 2011, Jiao et al. [36] 
performed the exome sequencing of a set of well-characterized sporadic PNETs from 68 
patients. In total, somatic mutations in MEN1, death domain-associated protein (DAXX), 
alpha thalassemia/mental retardation X-linked (ATRX), and members of the mammalian 
target of rapamycin (mTOR) pathway (phosphatase and tensin homolog (PTEN), TSC2 and 
phosphatidylinositol 3-kinase (PIK3CA)) were identified in 44,1%, 25%, 17,6%, 7.3%, 8,8% 
and 1,4%, respectively. About 43% of the PNETs studied harboured a mutation in DAXX or 
ATRX which had not been reported previously and were mutually exclusive. This finding 
was consistent with the knowledge of their putative function within the same pathway, which 
will be explored further ahead. The authors also established these two genes as PNET 
tumor suppressor genes due to their high ratio of inactivating mutations. Another interesting 
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hypothesis was raised by the authors due to the differences in survival of the patients, in 
which the mutations in MEN1 and DAXX/ATRX could identify a biologically specific 
subgroup of PNETs with prolonged survival; recent studies have not been concordant with 
the previous findings [35, 37, 38]. Lastly, 14% of the tumors with mutations in members of 
the mTOR pathway were of special interest due to the availability of inhibitors of the mTOR 
pathway for patient treatment.  
More recently, the whole genome landscape of PNETs was analysed in 102 
clinically sporadic tumors [35]. The aim was to define the molecular pathology of these 
tumors more extensively, as well as to identify novel candidate mechanisms of 
pathogenesis. In a small subset of the studied PNETs a novel mutational signature was 
found. It referred to somatic pathogenic mutations or germline inactivating mutations in the 
base-excision-repair gene MUTYH-associated polyposis (MAP). MAP is characterized by 
an increased lifetime risk of colorectal cancer with the development of colonic adenomatous 
polyps, a smaller risk of duodenal cancer development, and a moderate risk for 
extraintestinal malignancies, such as ovarian, bladder and skin cancers, with a tendency 
for breast cancer [39]. The data from Scarpa et al. [35] suggests an additional role for 
MUTYH deficiency in PNETs. The discovery of these deleterious mutations in MUTYH 
prompted the authors to screen the germline DNA of all patients: 6 deleterious germline 
MEN1 mutations were found, as well as single novel truncating germline mutations in cyclin 
dependent kinase inhibitor 1B (CDKNB1) and VHL. The germline mutations were 
associated with somatic LOH in each of the previous cases. The checkpoint kinase 
(CHEK2), a DNA-damage repair tumor suppressor gene in breast cancer and other 
cancers, was also found to present predicted damaging germline variants in a small number 
of cases (4%). As for somatic driver mutations in PNETs, the data from these authors is 
consistent with previous literature reports, adding some new findings. MEN1 was the most 
frequently mutated of the studied genes, with a prevalence of 37% within these tumors. 
Mutually exclusive inactivating mutations in DAXX and ATRX were found respectively in 
22% and 10% of the study sample, consistent with the report of Jiao et al. (2011) and other 
authors throughout the recent years [40, 41]. Additionally, mTOR pathway genes PTEN and 
DEP domain containing 5 (DEPDC5) were also frequently mutated, as well as the mTOR 
pathway’s negative regulators TSC1 and TSC2; PTEN mutations were mutually exclusive 
from mutations in the latter genes. The histone modifier SET domain containing 2 (SETD2) 
was also found to be mutated in a small subset of the tumors (5%). Overall, four pathways 
were reported to be commonly altered in PNETs: i) DNA damage repair (MUTYH, CHEK2, 
BRCA2); ii) Chromatin remodelling (MEN1, SETD2); iii) Telomere maintenance and altered 
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telomere length (DAXX, ATRX); iv) and, mTOR pathway activation (PTEN, DEPDC5, TSC1, 
TSC2) [35].   
It is important to emphasize the findings regarding DAXX and ATRX consistent with 
previous reports: they were present in one third of the studied PNETs and correlated with 
somatic telomere repeat content and telomere length, mainly by activation of the alternative 
lengthening of telomeres, the so-called ALT pathway. As mentioned above, according to 
Jiao et al. [36] tumor mutations in MEN1, DAXX/ATRX or the combination of both MEN1 
and DAXX/ATRX mutations were associated with prolonged survival relatively to wild-type 
patients. Contrarily to the initial observations, Marinoni et al. [37] demonstrated that patients 
with DAXX/ATRX protein loss presented a poorer disease outcome associated with tumor 
size and metastasis, as well as a reduced relapse-free survival and increased tumor-
specific death. The previous results have been further confirmed in two other recent studies 
reporting the association between DAXX/ATRX loss in PNETs with aggressive 
clinicopathological features and shorter disease-free-survival and disease-specific-survival 
[38, 42].  
The contradictory results obtained from these studies may reflect different cohorts 
and different stages enrichment of the patient sample: the recent studies [37, 38, 42] had 
more diverse samples when compared to the original study [36], in which most patients 
presented highly aggressive tumors and metastatic disease.  Nevertheless, mutations in 
DAXX/ATRX are likely to define biologically specific subgroups of PNETs and may be useful 
to predict patient outcome in a stage-specific manner.  
 
1.4. Alpha-Thalassaemia/Mental Retardation X-linked (ATRX) 
 
ATRX is located on the long arm of the human X chromosome (Xq21.1) and it 
encompasses 36 exons. The gene is highly conserved between mouse and human, having 
an homology of 85% [43]. The respective protein is a member of the SNF2 subgroup of the 
SWItch/sucrose non-fermentable (SWI/SNF) protein family protein; its members have been 
shown to modulate a number of cellular processes such as transcription, DNA repair, mitotic 
recombination and to remodel chromatin through ATP hydrolysis. The 280 kDa protein 
contains two highly conserved domains: a globular N-terminal plant homeodomain (PHD) 
denominated ATRX-DNMT3-DNMT3L (ADD) domain and seven helicase subdomains 
located at the C-terminus that confer ATPase chromatin remodelling activity to the protein 
[43-47]. A truncated isoform of ATRX, ATRXt (200 kDa), was demonstrated to be produced 
when intron 11 is not spliced from the primary transcript, retaining the PHD domain but not 
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the SNF2 domain (figure 3). Like the full-length protein, ATRXt is highly conserved between 
mouse and human homologues [46-48].    
 
Figure 3. Schematic representation of the ATRX gene; the boxes represent the 36 
exons (top row). The full-length protein (280 kDa) is represented on the down row; 
the truncated isoform (200 kDa) is shown on the middle row. 
 
SWI/SNF protein family members are widely implicated in cancer and other human 
syndromes of mental retardation and genomic instability [48-50]. Mutations in ATRX were 
originally identified in patients with X-linked alpha thalassaemia mental retardation 
syndrome, a rare disease with an uncertain prevalence estimated to be less than 10 people 
per million [51].  Male patients present not only alpha thalassemia (caused by reduced 
production of structurally intact α-globin genes), but also developmental delay, facial 
abnormalities, gonadal dysgenesis, skeletal abnormalities, short stature, seizures, cardiac 
defects and renal urinary abnormalities. Female carriers tend to be physically and 
intellectually normal [49-52].  
ATRX is expressed exclusively in the nucleus. Immunofluorescence studies have 
demonstrated a preference binding of the protein within promyelocytic leukaemia (PML) 
nuclear bodies and to repetitive heterochromatic regions, such as telomeric and pericentric 
DNA repeats and ribosomal DNA. It has already been demonstrated that guanidine (G)-rich 
repeats can lead to the formation of G-quadruplexes DNA (G4-DNA) structures. Telomeric 
DNA is particularly prone to form these secondary structures, which are known to form 
barriers to several nuclear processes (DNA replication, transcription) due to their capacity 
of inducing replication fork stalling, leading to replicative stress and ultimately DNA damage 
that requires reparation. ATRX, as a chromatin remodeler, is recruited to telomere ends, 
participating in the resolution of these G4 secondary structures by directly binding to them, 
as it was previously shown in vitro [45]. ATRX loss is therefore thought to cause genomic 
instability by failing to prevent the formation of G-quadruplexes [43-45, 50, 53, 54].  
An increasing number of studies has focused on the many functions of ATRX in 
establishment and/or maintenance of the telomeres stability. The mechanism of chromatin 
 12 
stability in which ATRX is involved also comprises DAXX protein; their interaction is vital for 
the deposition of the histone variant H3.3 at these regions of the genome, as it will be further 
explored.  
 
1.5. Death domain associated protein  
 
DAXX is a highly conserved protein associated with both nuclear and cytoplasmic 
events during apoptosis. It was firstly identified in the cytoplasm as a protein that binds to 
the death domain of the transmembrane death receptor FAS, potentiating FAS-induced 
apoptosis. The nuclear DAXX molecules associate with PML bodies and other subnuclear 
domains [53, 55].  
 
1.6. ATRX/DAXX complex and deposition of H3.3  
 
Histones are the main protein components of chromatin with the function of 
packaging and organizing DNA at its fundamental unit: the nucleosome. The nucleosome’s 
core is composed of a hetero-octamer of histones, comprising a tetramer of (H3-H4)2 
flanked by two dimers of H2A-H2B [56, 57]. This highly organized dynamic permits the 
compaction of the genome, while enabling cellular processes such as transcription, 
replication, recombination and repair at the same time [54]. Histone variants differ from their 
primary sequences and they emerged as an important way to control chromatin function by 
altering the biochemical structure of the nucleosome. In mammals, five Histone 3 variants 
have been identified so far. H3.3 is a conserved histone variant with 96% of homology when 
compared to the major specie H3.1. The canonical histone H3.1 is synthetized in the S-
phase and deposited only during DNA replication but H3.3 is expressed throughout the cell 
cycle [54, 57, 58]. The slight substitutions in H3.3 relatively to its canonical counterpart are 
thought to mediate interactions with chaperone complexes which are unique to this variant 
and facilitate its replication-independent deposition. H3.3 has been  considered as a mark 
of transcriptional activity [59]. However, recent studies have enlightened the enrichment of 
H3.3 at telomeres or centromeres which are silent chromatin loci [49, 60, 61].  
A robust interaction between DAXX and ATRX has been described: they are 
components of the same ATP-dependent chromatin-remodelling complex. DAXX interacts 
with the linker region of ATRX located between the ADD and ATPase domains. This 
complex was found to be essential for the deposition of H3.3 at telomeres and pericentric 
heterochromatin to maintain telomere integrity [43, 50, 54, 58, 60, 62]. ATRX acts as a 
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chromatin remodeler, being responsible for recruiting DAXX to telomeres, while DAXX acts 
as a specific H3.3 chaperone [49, 54, 58].  
 
1.7. Alternative Lengthening of Telomeres (ALT) 
 
Telomeric DNA presents G-rich sequences that can be synthesized by telomerase, 
a reverse transcriptase enzyme. Continued cell proliferation eventually leads to senescence 
or apoptosis since most somatic tissues do not have sufficient telomerase activity to prevent 
telomere attrition [63].  
The process of tumorigenesis usually depends on extensive cell proliferation and on 
the avoidance of telomere shortening and senescence to acquire immortality, which is 
considered one of the major hallmarks of cancer [64]. About 85% of all cancers achieve 
immortality through the reactivation of telomerase; however, the remaining 10-15% 
maintain their telomere length by a telomerase-independent mechanism – Alternative 
Lengthening of Telomeres (ALT) [44, 53, 63, 65, 66]. Cells with the ALT pathway activated 
exhibit different characteristics when compared to the ones that express the telomerase 
subunit (TERT). Those differences include telomere length heterogeneity, ranging from 
undetectable to extremely long, a finding consistently demonstrated by telomere specific in 
situ hybridization (tel-FISH) [66, 67]; telomere recombination with the presence of 
extrachromosomal (linear and circular) telomeric repeats [68]; high frequency of telomeric 
sister chromatid exchange events [43, 69]; and the observation of ALT-associated PML 
nuclear bodies (APBs) that differ from the common PML nuclear bodies [63, 70].  
The cells that present an ALT phenotype depend on homologous recombination 
(HR) DNA-repair mechanism to maintain their telomere length. According to this hypothesis, 
the synthesis of new telomeric DNA mediated by recombination uses an existing telomeric 
sequence from an adjacent chromosomal telomere as a copy template [63, 66]. However, 
this mechanism was still poorly understood and insufficiently characterized. In 2016, Dilley 
et al. [71] defined the break-induced telomere synthesis and demonstrated a specialized 
replisome underlying ALT telomere maintenance.  
While epithelial cancers rely more frequently on telomerase reactivation or re-
expression, tumors of mesenchymal origin are reported to activate ALT more frequently. 
ALT phenotype is more prevalent in neuroblastomas, tumors of the central nervous system 
(astrocytoma, glioblastoma, oligodendroglioma and medulloblastoma), sarcomas 
(osteosarcoma, leiomyosarcoma, liposarcoma and chondrosarcomas) and neuroendocrine 
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tumors (pancreatic and paragangliomas). The mechanism has also been observed in 
common cancers, such as breast carcinoma [53, 63, 72].  
In 2012, Lovejoy et al. [72] reported ATRX to be either undetectable or severely 
depleted in approximately 90% of human ALT cell lines, results that established a strong 
correlation between the initiation or maintenance of ALT and a deficiency in the 
DAXX/ATRX pathway. There is a strong suggestion that ATRX acts as a suppressor of the 
ALT pathway since mutations in ATRX and/or DAXX found in recent high throughput 
genome sequencing of a variety of ALT expressing tumors appear to be mutually exclusive 
to mutations in the TERT promoter that lead to telomerase re-expression.  
The theoretical mechanism of DAXX/ATRX role in chromatin landscaping and 
initiation of ALT involves the previously mentioned G4-DNA secondary structures. ATRX 
localization to heterochromatin by binding to the histone variant H3.3 occurs through 
interaction of its ADD domain with an H3.3 N-terminal tail, trimethylated at Lys9 (H3K9me3) 
and unmodified at Lys4 (H3K4me0) and also through interaction with heterochromatin 
protein 1 (HP1). When ATRX arrives to its binding site, it facilitates the deposition of H3.3 
in combination with DAXX. This deposition is thought to induce chromatin changes that 
prevent the formation of the previously mentioned G4-DNA structures [53].  
 
 
 
 
 
 
 
 
 
G4-DNA secondary structures are associated with increased stalling of replication 
forks at telomeric sites, which is a known trigger of HR, an event that gathers increasingly 
more evidence to be determinant of the ALT pathway [44, 53, 65]. By preventing the 
formation of G4 structures through the deposition of H3.3 in combination with DAXX, ATRX 
plays a central role in ALT cells.  
Figure 4. Schematic mechanism for ATRX/DAXX chromatin landscaping through 
deposition of H3.3 and interaction with G4-DNA structures. Amorim et al. [53]. 
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This complex of chromatin remodelling is therefore fundamental in the repression of 
ALT. All these observations and understand of the way ATRX operates may provide clues 
for future development of therapies to treat tumors with an ALT background [43, 63, 65, 66, 
72]. 
 
1.8. ALT in the context of PNETs 
 
As previously stated, mutations in the DAXX/ATRX pathway represent the second 
most common somatic genetic event in PNETs, following mutations in MEN1 gene [35, 36, 
43]. These novel tumor suppressor genes interact with one another to function in chromatin 
remodeling at telomeric regions. Mutations in either one of the genes are associated with 
loss of nuclear expression of the respective proteins by immunohistochemistry. The 
telomere status in PNETs in which ATRX and DAXX mutational status had been previously 
determined was therefore evaluated to correlate it with the ALT phenotype.  
In 2011, Heaphy et al. [41] performed telomere-specific tel-FISH in a sample of 41 
PNETs. In 25 of them (61%) ultrabright telomere FISH signals were detected which is a 
characteristic feature of the ALT due to unbalanced telomere length. Of the studied 41 
tumors, 19 presented mutations either in ATRX or DAXX; all the mutated cases were ALT-
positive. Additionally, 6 tumors with no detectable mutations in both genes were also ALT-
positive. These results pointed to a perfect correlation between ATRX or DAXX inactivation 
and the presence of ALT phenotype in these tumors.  
In 2012, deWilde et al. [40] evaluated the loss of the proteins’ expression and 
acquisition of the ALT phenotype, this time in a subset of MEN1 syndrome associated 
PNETs. In their study, loss of nuclear expression of ATRX and/or DAXX occurred in 6% of 
MEN1 well-differentiated PNETs; this loss of expression perfectly correlated with the 
presence of the ALT phenotype. Our group reported an incidence of 7% of TERT promoter 
mutations in their study sample and the majority of cases had germline mutations in MEN1 
or VHL [73]. This finding suggests that PNETs associated with hereditary syndromes may 
rely on other types of mechanisms to maintain their telomere length. 
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1.9. Animal models 
 
The observation of the initiation, development and progression of tumorigenesis in 
rare and heterogeneous neoplasms such as PNETs is of particular importance. However, 
the difficulty in obtaining appropriate patient tissue samples that allow the study of all 
tumorigenic stages makes it difficult to track the disease in human patients.  Animal models 
are fundamental tools for understanding and determining the pathogenesis, 
pathophysiology and natural history of PNETs. They allow specific genetic manipulation, as 
well as tissue retrieval at all stages of development or tumor presentation. Several animal 
models (mainly murine) have been created to study PNETs, derived from 3 approaches: 
transgenic expression of oncogenes under the insulin or preproglucagon promoters, 
mimicry of genetic abnormalities of human PNET syndromes or unexpected findings in 
animal models with initial different purposes [74]. Hanahan et al. [75] and Alliouachene et 
al. [76] generated two mouse models using the insulin promoter to drive the expression of 
different oncogenes. Two other mouse models were created also to drive oncogenic 
expression under the control of the preproglucagon promoter [77, 78]. Related to the 
induction of genetic abnormalities, several studies have deleted MEN1 making use of 
different genetic tools. Crabtree et al. [79] and Bertolino et al. [80] generated mouse models 
with a general heterozygous MEN1 deletion. Posterior studies introduced novel mice to 
overcome lethality of homozygotes and to achieve a conditional deletion of the gene in 
specific cell types: pancreatic β-cells [81-83] and pancreatic α-cells [84, 85]. Another model 
developed by Shen et al. [86] was characterized by a pancreas-specific homozygous MEN1 
deletion.  
 
1.9.1. Cre-loxP system in animal models  
 
The Cre-loxP site specific recombination system is demonstrated to be an efficient 
method to mediate tissue-restricted ablation of target genes. The cyclisation recombination 
(Cre) enzyme of the bacteriophage P1 is a 38 kDa site-specific recombinase [87], that has  
34 bp DNA recognition sequences called loxP sites (locus of X-over P1). Each loxP consists 
of a 13 bp inverted repeat sequences flaking a central directional core of 8 bp as illustrated 
in figure 5. Specific DNA sequences flanked by loxP sequences placed on the same strand 
are said to be ‘floxed’ and they are excised by the Cre-mediated recombination [88-95].   
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For the recombination to take place in vivo, Cre recombinase itself must be 
expressed within the target cells. For this to happen, Cre recombinase, as an exogenous 
gene, must be inserted downstream of a promoter to drive expression, being the choice of 
promoter that defines specificity of the protein’s expression in a tissue- or cell-specific 
manner [89, 96-99].  
At least 21 endocrine cell-type-specific driver lines have been created so far [89, 
93], most of them employing the rat insulin promoter (RIP) to direct β-cell-specific transgene 
expression. The mouse strain in question is commonly referred to as RIP-Cre, in which 
expression of Cre recombinase is controlled by a fragment of the rat insulin II gene 
promoter. Studies from several different laboratories have reported high levels of transgene 
expression within pancreatic β-cells, reaching 80% or more of efficacy of recombination [93, 
97, 99-101].  
 
1.9.2. Knockout model 
 
The used transgenic mice were designed using the RIP-Cre/LoxP system. 
C57BL/6TgN(Ins2-Cre)25Mgn mice (RIP-Cre) are generated by injection into B6D2(F2) pronuclei 
of a transgene containing a 669 bp fragment of the rat insulin II promoter, nuclear localized 
Cre recombinase and a 2.1 kbp fragment from the human growth hormone. The allele is 
subsequently moved to a C57BL/6J background [102]. These mice are phenotypically 
normal and overexpress Cre recombinase specifically in the β-cells of pancreas.  
To perform the conditional knockout, another strain of transgenic mice has been 
used: C57BL/6ATRX’/LoxP. These flox mice carry the ATRX gene floxed, with a floxed Neor 
cassette inserted within intron 17 and loxP sites flanking exon 18 [47, 48, 103]. The goal is 
to perform a target deletion of exon 18 in the ATRX gene, which encodes the first of seven 
motifs that compose the conserved SNF2-like ATPase/Helicase domain of ATRX, a feature 
of chromatin-remodelling proteins that has been found to harbour disease-causing 
 Figure 5. The loxP system consists of an 8 bp core 
region flanked by two 13 bp inverted repeats. 
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mutations in several pathologies, including PNETs [44-47]. Deletion of the specific exon 
leads to the disruption of this domain. Excising exon 18 still allows the production of the 
shorter isoform of the protein (ATRXt), comprising exons 1 to 11 [46-48].  
 
 
Figure 6. Strategy for targeted deletion of exon 18 of the ATRX gene. Adapted from 
Bérubé et al. (2005) and Garrick et al. (2006). 
 
 
 
Once Cre recombinase is expressed in the β-cells of the endocrine pancreas and 
recognizes loxP sites, exon 18 will be conditionally excised [89, 98, 99], thus generating a 
mouse with ATRX disrupted in this specific type of cells. 
 
As above stated, a great progress has been made in the last few years regarding 
the molecular pathogenesis of PNETs. Breakthrough studies reported a high prevalence of 
mutations in either ATRX or DAXX, and such finding paved the way for other studies to 
confirm and consolidate these findings in the disease. However, a deeper understanding of 
the role of this alteration in the disease is required to improve a better knowledge in the 
diagnosis, prognosis and/or treatment of the disease. The warranted study of tumorigenesis 
in vivo in this context prompted us to develop a mouse model in which ATRX is conditionally 
deleted in the pancreatic β-cells – an ATRX conditional knockout mice. 
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2. OBJECTIVES 
 
 
The general aim of this project was to evaluate a novel mouse model of pancreatic 
neuroendocrine tumors – an ATRX conditional knockout model.  
In order to fulfil our objective several tasks were defined. The initial approach defined 
was to characterize our population composition. For this goal, we evaluated the Cre-Lox 
operational system by genotyping the mice that were included in the study. The next 
objective was the histological evaluation of the pancreas of the animals. This part consisted 
in a microscopic evaluation of features present in study animals, and since it was a 
conditional deletion in specific cells, to characterize this endocrine population. A final task 
was the creation/optimization of tools that will be further used in the exploration of this 
model. 
  
 20 
  
 21 
3. MATERIALS AND METHODS 
 
3.1. Generation of ATRX conditional knockout mice  
 
To generate the conditional knockout of ATRX in the pancreas β-cells we performed 
the crossing of the two mouse strains above stated. The crossings were performed to obtain 
an offspring with distinct genetic backgrounds and, therefore, allow the creation of 3 
experimental groups regarding ATRX status: control, heterozygous and homozygous 
groups.   
The control group comprises animals from both genders without loxP sites flaking 
exon 18 of ATRX, that maintain the gene undisrupted in their genome.  
The heterozygous group is composed exclusively by female mice, since ATRX is 
located on chromosome X. They present loxP sites flanking ATRX in only one of the alleles 
giving rise to heterozygous animals.  
The homozygous group comprises both genders. If it is a female, ATRX will be 
flanked by loxP sites in both alleles; if it is a male, only one of its alleles is loxP flanked.  
The possible genotypes, mating schemes and respective possible offspring are 
summarized in figure 7. 
 
Figure 7. Animals genotypes, mating schemes and expected offspring. 
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3.2. Study sample  
 
 The study sample is composed of 161 animals of which 75 (46,6%) are males and 
86 (53,4%) are females.  
 For each animal, the pancreas was collected and a fragment was formalin-fixed and 
paraffin-embedded (FFPE) for posterior histological examination. For the majority of 
individuals and when feasible, other organs were collected, such as spleen, lungs and liver, 
or other organs revealing macroscopic alterations. Other organs were collected less 
frequently in the population, such as kidneys, ovaries, skin and thymus and processed 
equally for posterior histological evaluation. A series of biological material were also stored 
in a biobank, such as urine, blood and serum samples at -80 ºC.   
 
3.3. DNA Extraction from Formalin-fixed Paraffin Embedded Tissues (FFPE)  
  
 For each FFPE sample, the slides were deparaffinized with xylene and cleaned with 
absolute ethanol. Lysis solution (300 μL Citogene kit, Citomed, Portugal) was performed to 
lysate cells, followed by the addition of proteinase K (15 μL of a 20mg/mL solution; P2308, 
Sigma-Aldrich, USA) which was left overnight at 55ºC under agitation for protein 
degradation. The next day, an additional 10 μL of proteinase k could be added if the 
digestion was not complete. DNA extraction continued with using a protein precipitation 
solution (100 μL Citogene kit, Citomed), followed by DNA precipitation with isopropanol and 
a series of washes with hydrated alcohols. The final elution was in 20 μL of DNAse/RNAse-
free water and DNA concentration was measured by spectrophotometry (Nanodrop Lite, 
Thermo fisher scientific, USA). The DNA samples were stored at -20ºC.  
 
3.4. Genotyping of the sample 
 
The confirmation of the Cre-LoxP status was performed by RIP-Cre transgene and 
LoxP-insert specific alleles detection by PCR. To this purpose a multiplex assay was 
developed for the detection of the loxP sequences with the primers ATRX_int17_F 
(GGAGAGGGAAGGAGGAAATG) and ATRX_int17_R (TAGCCATACCTGCAACCACA) 
and for the RIP-Cre transgene with oIMR1084_F (GCGGTCTGGCAGTAAAAACTATC) and 
oIMR1085_R (GTGAAACAGCATTGCTGTCACTT). The reaction was constituted by 3.5 μL 
of H2O, 5 μL of master mix (MyTaq, Bioline, UK), 0.25 μL of each primer and up to 0,1 μg 
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of genomic DNA. The cycling program was 5 minutes at 95ºC for initial denaturation, and a 
set of 30 cycles composed of a 30 seconds denaturation at 95ºC, 90 seconds of annealing 
at 60ºC and 30 seconds of extension at 72ºC. A final extension was performed at 72ºC for 
5 minutes.  The multiplex assay developed can retrieve in the presence of loxP sequences 
a fragment of 199 base pairs (bps), whereas it absence presents a wildtype fragment of 150 
bps. The present of the transgene RIP-Cre is confirmed by the presence of a 102 bps 
fragment.  
 
3.5. Hematoxylin-Eosin staining 
 
FFPE sections of the various organ tissues collected from each animal of the study 
sample were prepared with Hematoxylin-Eosin staining. The slides were deparaffinized in 
xylene and rehydrated in a sequence of graded alcohols (100%; 95%; 70%) until they were 
placed in running water. Following rehydration, slides were stained with Gill’s Hematoxylin 
(72411, Richard-Allan Scientific Gill, Thermo Fisher Scientific, USA) for 4 minutes, after 
which they were washed in running water. Slides were then stained with Eosin (Richard-
Allan Scientific Eosin, Thermo Fisher Scientific) for 4 minutes. Dehydration was performed 
in an inverted sequence of the graded alcohols (70%; 95%; 100%) and placed in xylene 
before mounting with appropriate medium.  
 
3.6. Immunohistochemistry  
 
Immunohistochemistry optimization was performed for different primary antibodies. 
The base protocol consists of deparaffinization with xylene and rehydration in a sequence 
of graded alcohols (100%; 95%; 70%) followed by heat induced antigen retrieval (HIER) in 
citrate buffer 100x, pH=6 (AP-9003-500, Thermo Fisher Scientific). The methods of HIER 
will be described ahead for each protocol. Endogenous peroxidase blocking was performed 
with 30% hydrogen peroxide diluted in methanol (1:10) for 10 minutes. Tissue blocking and 
primary/secondary antibody incubation will be described for each protocol. Amplification 
and detection of the target antigen signal is performed with avidin-biotin complex (PK-400, 
Vector Laboratories, USA) diluted 1:100 in antibody diluent (TA-125-ADQ, Thermo Fisher 
Scientific). For the detection, 3,3’-diaminobenzidine (DAB) (K3468, Dako, USA) was used 
in the proportion of 20μL to 1mL of the respective substrate, retrieving a brownish colour. 
Other substrate colours (purple) were obtained with immPact VIP kit (SK-4605, Vectastain, 
USA). Slides were counterstained with Gill’s Hematoxylin (72411, Richard-Allan Scientific 
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Gill, Thermo Fisher Scientific), sequentially dehydrated and mounted. All the washing steps 
were performed with Tris-buffered saline (TBS) buffer (10%).  
 
3.6.1. Ki-67 
HIER was performed in a pressure cooker in citrate buffer 10x (pH=6). The antigen 
retrieval proceeded as follows: 1 minute at 65 ºC and 10 minutes at 125 ºC. Tissue blocking 
was performed with swine serum (X0901, Dako) diluted 1:5 in antibody diluent for 30 
minutes in humid chamber at room temperature (RT). Incubation with primary antibody 
rabbit monoclonal antibody clone SP6 anti-Ki-67 (275R-1, Sigma-Aldrich) was performed 
overnight at 4ºC in a dilution of 1:100 in antibody diluent. Incubation with secondary 
antibody, biotinylated swine anti-rabbit immunoglobulins (E0353, Dako) diluted 1:100, was 
performed for 30 minutes in humid chamber at RT.  
 
3.6.2. Chromogranin A 
HIER was performed in a steamer set in citrate buffer 10x (pH=6) for 45 minutes. 
Tissue blocking was performed with swine serum diluted 1:5 in antibody diluent for 30 
minutes in humid chamber at RT. Incubation with primary antibody rabbit polyclonal 
antibody anti-chromogranin A (259003, Synaptic Systems, Germany) was performed for 1 
hour at RT in a dilution of 1:400. Incubation with secondary antibody biotinylated swine anti-
rabbit immunoglobulins diluted 1:100 was performed for 30 minutes in humid chamber at 
RT.  
 
3.6.3. Synaptophysin 
HIER was performed in a steamer set in citrate buffer 10x (pH=6) for 45 minutes. 
Tissue blocking was performed with swine serum diluted 1:5 in antibody diluent for 30 
minutes in humid chamber at RT. Incubation with primary antibody rabbit monoclonal clone 
SP11 antibody anti-synaptophysin (RM-9111-S0, Thermo Scientific) was performed for 1 
hour at RT in a dilution of 1:100. Incubation with secondary antibody biotinylated swine anti-
rabbit immunoglobulins diluted 1:100 was performed for 30 minutes in humid chamber at 
RT.  
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3.6.4. Cre-recombinase 
HIER was performed in a steamer set in citrate buffer 10x (pH=6) for 40 minutes. 
Tissue blocking was performed with swine serum diluted 1:5 in antibody diluent for 30 
minutes in humid chamber at RT. An additional incubation with mouse serum (S2160-020, 
Biowest, France) was performed for 1 hour at RT. Incubation with primary antibody rabbit 
polyclonal antibody anti-Cre (69050-3, Merck Millipore, USA) was performed overnight at 
4ºC in a dilution of 1:1000. Incubation with secondary antibody biotinylated swine anti-rabbit 
immunoglobulins was performed for 30 minutes diluted 1:100 in humid chamber at RT. 
 
3.6.5. ATRX 
HIER was performed in a steamer set in citrate buffer 10x (pH=6) for 40 minutes. 
Tissue blocking was performed with swine serum diluted 1:5 in antibody diluent for 30 
minutes in humid chamber at RT. Incubation with primary antibody rabbit polyclonal 
antibody anti-ATRX (HPA001906, Sigma-Aldrich) was performed overnight at 4ºC in a 
dilution of 1:500 in antibody diluent. Incubation with secondary antibody (biotinylated swine 
anti-Rabbit Immunoglobulins) was performed for 30 minutes diluted 1:100 in humid 
chamber at RT. 
 
3.6.6. Insulin 
HIER was performed in a steamer set in citrate buffer 10x (pH=6) for 40 minutes. 
Tissue blocking was performed with goat serum (X0907, Dako) diluted 1:5 in antibody 
diluent for 30 minutes in humid chamber at RT. Incubation with primary antibody mouse 
polyclonal antibody anti-insulin (18-0056, Zymed, USA) was performed overnight at 4ºC 
diluted 1:200. Incubation with secondary antibody biotinylated goat anti-mouse 
immunoglobulins was performed for 30 minutes diluted 1:100 in humid chamber at RT. 
 
3.6.7. Glucagon  
HIER was performed in a steamer set in citrate buffer 10x (pH=6) for 40 minutes. 
Tissue blocking was performed with swine serum diluted 1:5 in antibody diluent for 30 
minutes in humid chamber at RT. Incubation with primary antibody rabbit polyclonal 
antibody anti-glucagon ready-to-use (N1541, Dako) was performed for 1 hour in humid 
chamber at RT. Incubation with secondary antibody biotinylated swine anti-rabbit 
immunoglobulins was performed for 30 minutes diluted 1:100 in humid chamber at RT. 
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3.7. Ki-67 labelling index  
 
A set of 3 photos of each tumor were uploaded to the online software ImmunoRatio 
(http://153.1.200.58:8080/immunoratio/), that counts and retrieves a percentage of Ki-67 
immunostained cells by separating staining components (diaminobenzidine and 
hematoxylin) while applying an adaptive thresholding for nuclear area segmentation. The 
software provides an image with the ratio of DAB per nuclear area, while showing the cells 
it recognized as immunostained (please refer to appendix I).  
The final value of Ki-67 labelling index was obtained by calculating the mean of the 
percentage obtained for the 3 photos of each tumor case.  
 
3.8. Endocrine fraction measurement  
 
 The portion of endocrine area within the total pancreatic tissue of each animal was 
measured using the software ImageJ (https://imagej.nih.gov/ij/). A minimum of 9 photos of 
each pancreas slide were taken to achieve a minimum of 4.000.000 μM2 of tissue 
(comprising both exocrine and endocrine areas) and obtain an accurate and comparable 
percentage for each subject. The proper scale is introduced in the software so the results 
are obtained in the stipulated unit. We then performed the circumvention of the islets for the 
calculations. The programme therefore enabled the calculation of the areas inside the 
circumvented margins (appendix II). The colour threshold tool selects all tissue (endocrine 
and exocrine portions), deleting only the intra/interlobular areas of the pancreas, as well as 
blood vessels and pancreatic ducts (illustrated in appendix II). Both values obtained were 
used to calculate the endocrine counterpart size ratio within the total area of pancreatic 
tissue.  
 
3.9. Telomere-specific fluorescence in situ hybridization (tel-FISH)  
 
FFPE tissues were deparaffinized with xylene, rehydrated in a sequence of graded 
ethanol for analysis (100%; 95%; 70%) and washed in distilled water. The slides were then 
washed in 1% Tween 20 wash (99% distilled water, 1% Tween 20) for 1 minute. HIER was 
performed in citrate buffer 10x (pH=6) for 30 minutes in a steamer set. Following HIER, the 
slides were washed in distilled water for 1 minute and washed in 70%, 95% and 100% 
ethanol for analysis (6 minutes each). The slides were then allowed to completely dry before 
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applying the probe mix (the components and final concentrations are described in table 1). 
Following the application of the probe mix and the coverslip, the slides were denatured at 
84ºC for 5 minutes in a hybridizer (Dako Citomation, Dako). The slides hybridized for 2 
hours at RT in a dark humidified chamber. Following hybridization, the tissue slides were 
washed twice for 15 minutes in peptide nucleic acid (PNA) wash buffer (70% of deionized 
formamide, 29% of distilled water and 1% of 1M Tris HCl, pH 7.5), 3 times in PBS-T (0,1%) 
for 5 minutes and finally dehydrated in a sequence of graded ethanol for analysis (70%; 
95%; 100%) for 5 minutes each. The slides were then allowed to completely dry in a dark 
chamber; when dry, they were mounted in vectashield without DAPI (H-1000, Vector 
Laboratories) and vectashield with DAPI (H-1200, Vector Laboratories) in a proportion of 
3:1. The slides were stored at 4ºC in a dark chamber. The protocol was adapted from 
Cesare et al. (2015) [104].  
 
 
Table 1. Preparation of telomere-specific FISH probe mix 
 
Stock solution 1 slide (25 µl) Final concentration 
0.1M Na2HPO4 2.5 10 mM 
1M NaCl 0.25 10 mM 
1M Tris pH 7.5 0.25 10 mM 
Deionized formamide 17.5 70% 
Probe (67 µg/ml) 0.3 0.8 µg/ml) 
dH2O 3.95 - 
 
 
 
3.10. Immunofluorescence and telomere-specific FISH 
 
FFPE tissues were deparaffinized with xylene and rehydrated in a sequence of 
graded ethanol for analysis (100%; 95%; 70%). The slides were then washed in distilled 
water and 1% Tween 20 wash for 1 minute. HIER was performed in citrate buffer 10x (pH=6) 
for 30 minutes in a steamer set. Slides were washed in PBS-T 3 times for 5 minutes, and 
then incubated with goat serum for 30 minutes. Incubation with primary antibody mouse 
polyclonal antibody anti-insulin was performed for 2 hours at RT in a dark chamber. 
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Incubation with secondary antibody goat anti-mouse Alexa Fluor 594 (Z25007, Invitrogen, 
USA) was performed for 30 minutes at RT in dark chamber. After PBS-T washing, the slides 
were fixated in 10% formalin in distilled water for 20 minutes after which they were allowed 
to dry. Following the application of the probe mix (as described in table 1) and the coverslip, 
the slides were denatured at 84ºC for 10 minutes in a hybridizer. Hybridization was 
performed for 2 hours at RT in dark chamber. The slides were then washed twice for 15 
minutes with PNA wash buffer and 3 times for 5 minutes each in PBS-T. Dehydration in a 
sequence of graded ethanol for analysis followed (70%; 95; 100%), for 5 minutes each. 
After the slides dried, they were mounted in vectashield without DAPI and vectashield with 
DAPI in a proportion of 2:1. The slides were stored at 4ºC in a dark chamber. 
 
3.11. Statistical analysis 
 
Differences in leukocytic infiltration, insulitis, pancreatic lesions score and endocrine 
fraction among genotype and age groups were assessed by non-parametric Kruskall-Wallis 
test, followed by pairwise comparisons using Mann-Whitney U Test.  
Two-tailed P-values were derived from these statistical tests, using the program 
SPSS Version 24.0, Chicago, USA. The results were considered statistically significant at 
P < 0.05.  
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4. RESULTS 
 
4.1. Study population  
 
The study sample comprises 161 animals, of which 75 are males (46.6%) and 86 
(53.4%) are females. The age median is 16 (3-33) months. 
 
Table 2. Distribution of mice in age groups 
 
 Number (n) Percentage 
Less than 6 months 20 12.4 
6 – 12 months 27 16.8 
12 – 18 months 48 29.8 
More than 18 months 66 41.0 
 
 
4.2. Genotype Evaluation  
 
Allele-specific PCR was used for the confirmation of Cre recombinase transgene and 
loxP alleles identification in the mouse genomes. The following gel electrophoresis (figure 
8) illustrates the genotype assessment based in the presence or absence of amplification 
and respective fragment size as described below.  
 
 
 
 
 
 
 
 
 
 
 
 
CTRL 
 RIP-Cre+ 
RIP-Cre- 
  
 
loxP+  
 100 bps 
200 bps 
Marker 
Figure 8. Gel electrophoresis of allele-specific 
PCR for genotype evaluation (ATRX loxP and 
Cre detection). 
500 bps 
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Figure 9. Genotype distribution of the 
study sample. 
In the control sample lane, it is possible to detect 3 bands. The band with 102 bps 
(highlighted in blue) represents positivity for RIP-Cre transgene; when this band is not 
observed, the animal does not present the transgene in its genome.  
The band of 199 bp (highlighted in orange) represents the detection of loxP 
sequences. In this case, the animal is homozygous and its gender must be previously 
known: if it is a female, the genotype is ATRXFLOX/FLOX; if it is a male, the genotype is 
ATRXFLOX/Y, since ATRX is located on chromosome X. 
In case of a heterozygous animal for loxP, an intermediate band of 150 bp between 
the last two reported is observed (highlighted in green). Only female mice can be 
heterozygous (ATRXFLOX/X). Male mice are either controls or homozygous.   
 In case of positivity for the RIP-Cre transgene, but absence of loxP-inserts 
(highlighted in red) the subject is included in the control group.  
Following genotype evaluation, the study sample of our study was comprised by: 
39.1% (n=63) controls (of which 63.5% are males [n=40] and 36.5% [n=23] are females); 
36.6% [n=59] heterozygous mice; and 24.2% [n=39] homozygous mice (89.7% [n=35] 
males, 10.3% [n=4] females).  
 
 
 
 
 
 
 
 
 
 
  
   
 
 
 The study sample was then divided in two main genotype groups: controls (n=63) 
and ATRX floxed animals (n=98), which are further addressed as flox mice.  
 
 
Controls 
(n=63) 
Homozygous 
(n=39) 
Heterozygous 
(n=59) 
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4.3. Histopathological evaluation 
 
4.3.1. Pancreatic lesions 
The histological evaluation of pancreatic tissue slides of the subjects revealed a 
notable presence pancreatic lesions with a prominent role of inflammation in 141 of the 161 
(87.6%) animals. To categorize and evaluate the pancreatic lesions, a score with several 
criteria was adapted.  
Edema is caused by the retention of excess fluid within the body’s tissues and it was 
one of the parameters evaluated in the mice pancreas. The histological grading was 
adapted from Dembínski et al. [105] and uses a scale from 0 to 4: 0= absent; 1= interlobular 
edema; 2= interlobular and scarce intralobular edema; 3= interlobular and moderate 
intralobular edema; 4= interlobular and severe intralobular edema. Edema grading is 
illustrated in appendix IV.   
Vacuolization is also a criteria, referring to the percentage of acinar cells involved, 
using a scale from 0 to 3: 0= absent; 1= <25% acinar cells involved; 2= 25-50% of acinar 
cells involved; 3= >50% of acinar cells involved [105].  
Hemorrhagia was another of the parameters evaluated to assess pancreatic lesion. 
The adopted scale included the following scores: 0= absent; 1= 1-2 hemorrhagic foci per 
slide; 2= 3-5 hemorrhagic foci per slide; 3= >5 hemorrhagic foci per slide [105].  
To evaluate and quantify infiltration in the pancreas, two different parameters were 
considered: perivascular/periductal and diffuse leukocytic infiltration (LI) and infiltration in 
the pancreatic islets (insulitis). Leukocytic infiltration grading was adapted from Dembínski 
et al. [105] and uses a scale of 0 to 5: 0= absent; 1= scarce perivascular/periductal 
infiltration alone; 2= scarce perivascular/periductal infiltration and scarce diffuse infiltration; 
3= moderate perivascular/periductal and absent to scarce diffuse infiltration; 4= moderate 
perivascular/periductal and diffuse infiltration; 5= abundant diffuse infiltration. Insulitis was 
graded by adapting a scale from 0 to 4: 0= absent; 1= infiltrates in small foci at the islet 
periphery; 2= infiltrates surrounding the islet (peri-insulitis); 3= < 50% of intraislet infiltration; 
4= extensive infiltration, >50% of the islet. The scale was adapted from Papaccio et al. 
[106]. 
Below are illustrations representing some of the attributed grades of leukocytic 
infiltration, figure 10, as well as scores 1 to 4 for insulitis grading, figure 11.   
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Score 1 Score 3 
Score 5 Score 5 
Score 1 Score 2 
Score 3 Score 4 
Figure 10. Illustration of leukocytic infiltration grading (Scores 1, 3 and 5). 
Original magnification: 100X. 
Figure 11. Illustration of insulitis grading (Scores 1-4). Original magnification: 
100X. 
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The frequency of leukocytic infiltration and insulitis according to genotype (control 
and flox animals) and age groups (less than 6 months; 6 to 12 months; 12 to 18 months; 
more than 18 months) is shown below in figures 12 and 13, respectively.  
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Figure 12. Bar charts of LI frequency among (A) genotype groups and (B) 
age groups (Mann Whitney Test, *P < 0.05). 
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Leukocytic infiltration (LI) was absent in 27 of the 161 (19,1%) animals. The 
frequency of LI occurred with marked contrast between controls and flox mice in the highest 
scores: moderate perivascular/periductal and diffuse infiltration and abundant diffuse 
infiltration (scores 4 and 5, respectively; P > 0.05), as shown in figure 12 (A). There were 
significant differences of LI grade among age groups (P < 0.05). It was possible to observe 
that the highest levels of infiltration were present in the oldest animals (older than 1 year, 
with remarkable incidence in animals older than 18 months), whereas young mice present 
mainly a scarce perivascular/periductal infiltration (figure 12, B).  
 
 
 
 
 
 
 
A 
B 
Figure 13. Bar charts of insulitis frequency among (A) genotype groups 
and (B) age groups (Mann Whitney Test, *P < 0.05; **P < 0.01).  
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Insulitis was absent in 48 (29.8%) mice of the study sample. It was more pronounced 
in flox subjects when compared to controls in the group that presents small foci of infiltrates 
in the islet periphery (score 1; P > 0.05) and in the groups of intra-islet infiltration (scores 3 
and 4; P > 0.05), as shown in figure 13 A. When stratifying by age, there were significant 
differences regarding insulitis among the different groups and a notorious prevalence of 
severe insulitis (score 4) in mice older than 18 months, as shown in figure 13 B. Severe 
insulitis (score 4) was not found in mice younger than 12 months, figure 13 B. 
A final score to determine the grade of the lesions was built based on the sum of the 
5 evaluated parameters. Due to their higher pathological relevance, leukocytic infiltration 
and insulitis were accounted in the final score with a doubled weight value. Overall, the 
score ranged from 1 to 25 but for the descriptive analysis of the lesions, they were grouped 
in 3 main categories: 1 to 8 comprises low grade lesions, 9 to 20 includes moderate lesions 
and a score value of more than 20 comprises animals with high grade lesions. 38 of the 141 
(26.9%) animals presented low grade lesions; 84 (59,6%) presented moderate lesions and 
19 (13,5%) developed high grade lesions. The analysis of the pancreatic lesions score 
distributed by genotype and age groups is presented below in figure 14, A and B 
respectively.  
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Flox mice developed low, moderate and high-grade lesions more frequently (figure 
14, A). However, the differences of pancreatic lesions among the control and flox groups 
are not significant (P > 0.05). In the group of animals that develop high-grade lesions, the 
contrast among age groups is noteworthy, with a much higher frequency in mice with more 
than 18 months when compared to younger subjects. Low-grade lesions, moderate lesions 
and high-grade lesions presented significant differences among different age groups (P < 
0.05 and P < 0.001). 
 
4.3.2. Hyperplasia of pancreatic islets   
 
The histological evaluation of the mice pancreas also revealed a major increase in 
the endocrine area – hyperplasia of pancreatic islets.  
To assess the pancreatic endocrine portion, we used the software ImageJ as 
described in materials and methods for endocrine and exocrine area ratio quantification.  
 
 
B 
Figure 14. Bar charts for lesions score among (A) genotype and (B) age groups 
(Mann Whitney Test, *P < 0.05; **P < 0.001). 
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The analysis of pancreatic endocrine fraction revealed the existence of hyperplastic 
islets with a highly enlarged diameter compared to normal-sized islets, as illustrated in figure 
15.  
 
 
 
 
The median of endocrine fraction obtained for this population was 8.3%, with a 
minimum of 0.5% and a maximum of 34.1%.  
 The statistical analysis of the endocrine fraction regarding the genotype revealed a 
slightly higher median for controls than for flox mice (8.7 and 8.1, respectively; P > 0.05), 
illustrated in figure 16 A. Stratification by age groups, revealed that the medians are 
gradually higher (5.3, 6.8, 8.4 and 14.2, from young to older mice), with a significant 
difference among groups (P < 0.05 and P < 0.001), as represented in figure 16 B.    
 
 
 
 
 
B A 
Figure 15. Comparison of (A) a normal-sized islet with a mean diameter of 75 µm 
and (B) a hyperplasic islet with 940 µm of diameter. Original magnification: 100X. 
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Figure 1.  Figure 16. Boxplots of endocrine fraction among (A) genotype and (B) age groups 
(Mann Whitney Test; *P < 0.05, **P < 0.001). 
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Adding to their increased size, hyperplasic islets often present irregular shapes. 
Coalescence of adjacent islets is also very common. These features are represented in 
figure 17.     
 
4.3.3. Characterization of endocrine cell population 
 
To characterize the pancreatic endocrine cell population, immunohistochemistry for 
insulin and glucagon was performed. These hormones are produced by β- and α-cells, 
respectively. Together, these two types of cells comprise the majority of cell population of 
the islets, with a percentage of 60% to 80% and 15% to 20%, respectively. δ-cells (<10%) 
and PP-cells (<1%) represent only a very small fraction of this population. As expected, the 
architecture of normal-sized islets is represented by a β-cell core surrounded by α-cells in 
its periphery, as represented in figure 18. β-cells represent up to 85% of cell content, while 
α-cells represent about 10% of the endocrine population.  
A B 
Figure 17. Representation of (A) an irregular-shaped islet and (B) islet coalescence. 
Original magnifications: 100X and 40X, A and B, respectively.   
Figure 18. Immunohistochemistry staining of normal-sized islet for (A) insulin and 
(B) glucagon. Original magnification: 200X. 
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Hyperplasic and coalescent islets maintain their strong pattern of insulin expression, 
with staining in the majority of the islet population (figure 19, A and C). However, a 
homogenous expression of glucagon in the periphery of hyperplasic and irregular islets is 
not observed; instead, it presents itself in the middle of the endocrine portions and in a much 
less extent relatively to what is expected. This may point to a disrupted architecture of the 
islets (figure 19, B and D).  
 
 
Islets with mononuclear lymphocytic infiltrates in their surroundings or intra-islet 
infiltration continue to express insulin in the majority of cells, but, once again reveal a 
disrupted pattern of glucagon expression in their midst, as illustrated in figures 20 and 21.   
A B 
C D 
Figure 19. Immunohistochemistry staining of hyperplasic and coalescent islets 
for insulin (A, C) and glucagon (B, D). Original magnification: 40X. 
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A B 
A B 
C D 
Figure 21. Immunohistochemistry staining for insulin (A, B, C) and (D) glucagon in 
highly infiltrated islets. Original magnification: 200X. 
 
Figure 20. Immunohistochemistry staining for insulin (A) and glucagon (B) in islets with 
peri-insulitis. Original magnification: 100X. 
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4.3.4. Pancreatic Tumors 
 
Of the 161 studied mice, 20 (12.4%) presented pancreatic tumors. 15 out of the 20 
(75.0%) tumors arose in flox mice, while the remaining were in controls. The table below 
presents the genotype and age of the mice, as well as the ki-67 proliferative index of the 
tumors.  
      
 
Table 3. Description of pancreatic tumors in the study sample 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The differential diagnosis of PNETs can be obtained by immunohistochemistry using 
two classical markers that aid in lineage determination: chromogranin A (CgA) and 
synaptophysin (SYN). All 20 tumors were negative for both markers. Insulin is also not 
expressed in these tumors. The following images illustrate the architecture and 
immunohistochemistry staining pattern of the mentioned markers in one of the tumor 
samples. 
 
 
Genotype Age (months) Ki-67 index (%) 
ATRXFLOX/X 14 22,7 
ATRXX/Y 16 23,0 
ATRXFLOX/X 18 16,8 
ATRXFLOX/X 18 17,5 
ATRXX/Y 18 16,8 
ATRXFLOX/X 18 10,6 
ATRXX/Y 18 25,0 
ATRXFLOX/X 19 34,1 
ATRXX/Y 20 11,1 
ATRXFLOX/X 21 15,5 
ATRXX/Y 22 26,7 
ATRXFLOX/X 22 16,3 
ATRXFLOX/X 22 40,7 
ATRXFLOX/X 22 9,3 
ATRXFLOX/Y 22 20,5 
ATRXFLOX/X 22 41,9 
ATRXFLOX/X 22 13,8 
ATRXFLOX/Y 23 7,6 
ATRXFLOX/Y 24 70,0 
ATRXFLOX/X 24 59,8 
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A B 
C D 
Figure 22. Tumor stained with hematoxylin and eosin (H&E). Original magnifications: 
40X and 200X, respectively. 
Figure 23. IHC staining of a tumor sample for (A) CgA, (B) SYN, (C) insulin and (D) 
Ki-67. Internal controls are shown for CgA, SYN and insulin. Original 
magnifications: 40X and 100X.   
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4.4. Cre recombinase expression in pancreatic islets 
 
Genotyping confirms the presence or absence of RIP-Cre transgene in the mouse 
genome. However, as previously addressed, for recombination to take place in vivo, Cre 
recombinase needs to be expressed specifically in the nucleus of β-cells. 
Immunohistochemistry staining confirms the expression, as illustrated in figure 24. A 
heterogeneous pattern amongst islets of the same animal was observed: some present a 
high percentage of expressing cells, while other islets hold a lower fraction of expressing 
cells. 
 
 
 
 
4.5. ATRX expression in pancreatic islets 
 
As described in materials and methods, there are 3 main groups of mice in the study 
sample regarding ATRX status: controls (ATRXX/X or ATRXX/Y), heterozygous (ATRXFLOX/X) 
and homozygous (ATRXFLOX/FLOX or ATRXFLOX/Y) animals.  
 
 
 
A B 
Figure 24. Cre recombinase expression in the nucleus of pancreatic β-cells. 
Immunohistochemistry staining for (A) negative control and (B) RIP-Cre+/- mouse. Original 
magnification: 400X. 
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To evaluate the presence or absence of the protein in the pancreatic tissue, 
immunohistochemistry was performed. Control mice maintain the expression of ATRX in β-
cells, as well as heterozygous females, since the second allele is wild-type and the cells 
retain the capacity of producing the protein. Homozygous mice maintained expression of 
the protein, even if in a seemingly less extent. These results are illustrated in figure 25.  
 
 
 
 
 
 
 
 
 
 
A B 
C D 
Figure 25. ATRX expression in the nucleus of pancreatic β-cells. 
Immunohistochemistry staining for (A) negative control, (B) ATRXX/x mouse, (C) 
ATRXFLOX/X mouse and (D) ATRXFLOX/FLOX mouse. Original magnification: 400X. 
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4.6. Telomere FISH and Immunofluorescence  
 
In humans, ATRX mutations are known to induce the alternative lengthening of 
telomere mechanism, the so-called ALT mechanism. As previously mentioned, ALT, 
presents a typical phenotype that can be evaluated by FISH. To localize telomeres in the 
nucleus of pancreatic tissue, telomere-specific fluorescence in situ hybridization (tel-FISH) 
was performed. Telomeres are observed as bright green foci in the nuclei of cells (figure 
26). Additionally, to co-localize telomeric sequences specifically in pancreatic β-cells, 
immunofluorescence was combined with tel-FISH. In figure 27, telomeres are shown in 
green bright foci in the nucleus, while β-cells are visualized in red, since 
immunofluorescence was performed for the staining of insulin. Although at the moment, it 
was not possible do evaluate a considerable number of mice with this technique, the tool is 
optimized for further evaluation.  
Figure 27. Immunofluorescence for insulin combined with telomere-FISH to co-
localize telomeric DNA sequences within pancreatic islets. Original magnifications: 
630X and 1000X. 
 
Figure 26. Telomere-specific FISH in pancreas tissue. Original magnifications: 400X 
and 1000X. 
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5. DISCUSSION  
 
Animal models allow the study of a wide range of human diseases. In some cancer 
models, they enable researchers to follow tumorigenesis in a stepwise manner, something 
hard to achieve in human patients where tumors, generally, appear in different stages of 
development, not giving the opportunity to sometimes understand the first phases of 
tumorigenic development. Although rare, PNETs pose significant challenges to Clinicians. 
Their clinical manifestations often resemble other pathologies, which can result in a 
prolonged development as a result of a misdiagnose. Several animal models have been 
designed to mimic and understand the initiation and progress of tumorigenesis in PNETs, 
as reviewed by Babu et al. [74], but it is recognized that more animal models in the disease 
are needed. Most of the models addressed the most oncogenic event known in PETs, the 
MEN1 alterations. Since ATRX was recently reported with a high mutational frequency in 
PNETs [35, 36], a conditional knockout model was developed to allow the evaluation of the 
gene’s disruption in tumor development. At least 21 lines using endocrine genes have been 
used so far to drive Cre expression, 14 of which rely on insulin gene promoter [89]. Some 
of the most recent mouse models of PNETs have also employed the RIP-Cre system to 
conditionally delete MEN1 [80, 81, 83]. These studies reported a successful deletion of the 
gene, generating PNETs in the majority of the individuals.  
This study started by performing an overall histological evaluation of the mice 
pancreas in which inflammation was observed as a prominent finding, ranging from scarce 
perivascular or periductal foci of mononuclear lymphocytes to abundant diffuse infiltrates in 
the exocrine tissue (figure 10). Islet-associated mononuclear cell infiltration, termed insulitis, 
was also a very common finding (figure 11). Although not statistically significant (P > 0.05), 
the frequencies of the highest scores of leukocytic infiltration and insulitis were higher in 
flox mice when compared to controls (figure 12 A and 13 A). Both infiltrations were shown 
to progress with age: animals with more than 18 months of age presented remarkable 
higher levels of infiltration, while the majority of mice with 6 months of age or less had only 
scarce perivascular/periductal infiltrations or infiltrates in small foci at the islet periphery 
(figure 12 B and 13 B). The results were similar when an analysis was performed for the 
lesions score, including the grading of not only the leukocytic infiltration and insulitis but 
also edema, hemorrhagia and vacuolization (figure 14, A and B). Flox mice presented a 
higher tendency for developing moderate and high-grade lesions (figure 14 A); however, 
the difference among groups was not significant (P > 0.05). Age, on the other hand, proved 
to be determinant for the development of pancreatic lesions of higher grade; in fact, the 
majority of animals that developed these lesions were older than 18 months (figure 14 B).  
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Insulitis is a characteristic lymphocytic infiltration limited to the islets of Langerhans 
that arises alongside decreased β-cell mass in the context of diabetes type 1 [107]. In 1994, 
Campbell et al. [108] developed a transgenic mouse model with expression of interleukin 6 
(IL-6) controlled by the rat insulin promoter (RIP), promoting an overexpression specifically 
in β-cells. IL-6 is a cytokine that has been long proved to have an important role on the 
progression of auto-immunity and destruction of β-cells in diabetes type 1. The authors 
reported evidence of both peri- and intra-islet infiltration and an association of IL-6 with 
enlarged and often irregular-shaped islets. Similar to what happens in our model, the 
mononuclear cell infiltration was evidently more extensive in older mice. Their findings thus 
supported the hypothesis in which the localized production of this cytokine was sufficient to 
induce a progressive islet-specific inflammatory response [108]. This study also reported a 
disrupted architecture of the islets in terms of cell population, since a reduction in number 
and intensity staining of insulin positive cells was found. Pancreatic islets of our study 
sample do not present this kind of disruption: although severely enlarged (figure 15 B) and 
with an irregular shape (figure 17 A), the islets maintain their strong staining pattern of 
insulin staining throughout all their extension (figure 19, A and C). On the other hand, 
exocrine tissue damage or pancreatitis were not found in the model [108], contrarily to what 
happens in the individuals of our sample, in which a leukocytic infiltration outside the islets 
is found severe in older mice (figure 12 B) and with a seemingly higher tendency for 
developing in flox mice when compared to controls (figure 12 A).  
 As previously stated, it was found that the pancreatic islets of the ATRX conditional 
knockout mouse model were highly hyperplasic. It is important to emphasize that the normal 
portion of endocrine area of an adult mammalian is 1 to 2% on average [1]. Mouse islets 
are reported to have an average diameter of 116 µm, an increased value compared to 
human islets [4]. In the present model, the median of endocrine portion of the population is 
approximately 8%, with some subjects reaching an extreme of more than 30%, as portrayed 
in the boxplots of figure 16. These findings were verified in both flox mice and controls, with 
a slightly increased median for the latter as previously shown in figure 16 A, a difference 
which was not statistically significant (P > 0.05). The median of endocrine fraction 
significantly progressed as the animals’ age incremented (figure 16, B; P < 0.05 and P < 
0.001).  
Such results alerted us for studies in which the RIP-Cre strain was analyzed in order 
to determine if this animal per se could have alterations [93]. Results from three laboratories 
highlighted that even in the absence of genes targeted by loxP sites, RIP-Cre mice are 
glucose intolerant, with the possibility of impaired insulin secretion in its origin [93]. The 
authors also reported several cases of abnormal islet structure, with α-cells dispersed within 
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these complexes, instead of localized in their periphery [93], a pattern similar to the one we 
found, with an aberrant and scattered staining of glucagon in hyperplasic islets (figure 19, 
B and D). Another study investigated the background of the RIP-Cre strain and reported an 
increase in islet size in comparison to wild-type littermates, owing this to a possible 
morphologic response to impaired glucose [109]. The authors also pointed to the fact that 
while no reduction in islet number was observed, there was a reduction in β-cell mass 
(evidenced by the loss of insulin staining), which could be relevant for the development of 
glucose intolerance. In our study sample, we observe indeed a great increase of islet mass: 
instead of the reported 1-2% of endocrine portion of a normal pancreas in adult mammalians 
[1], we verified an increased median value of 8% for our study population (figure 16). This 
was significantly associated to mice aging (figure 16, B), as it was previously reported by 
other authors [109]. Our islets maintain their strong expression of insulin and their only 
architectural abnormality is dispersion of α-cells among the islet (figure 19, A-D).  
The endocrine portion of our mice is then highly hyperplasic, while maintaining a 
strong expression of insulin and an abnormal expression of glucagon, associated with both 
controls, flox mice and aging (figure 16). Adding to this, there is a high incidence of 
mononuclear cell infiltration in these islets (figure 13); insulitis has not been reported so far 
in any study relating to RIP-Cre mice. Infiltrated islets remarkably maintain their expression 
of insulin as previously shown in figures 20 (A) and 21 (A). The glucose intolerance and 
insulin impairment described for this strain need to be evaluated in our sample as they were 
proven to be almost a hallmark of RIP-Cre mice [93, 109]. However, these events induce 
β-cell mass reduction, which was not detected in the ATRX conditional knockout model 
(figure 19, A and C).   
We hypothesize that our control mice, which are all genotyped as RIP-Cre+/- are also 
associated with the onset of pancreatic lesions and endocrine fraction increase and that 
there are no significant differences of these features between RIP-Cre controls and RIP-
Cre/ATRX floxed animals. 
Several models have been reported to mimic PNETs. Crabtree et al. described a 
mouse model of MEN1 targeting by deleting 3 exons by homologous recombination. 
Homozygous embryos perished between days 11 to 13, while in the heterozygous 
population, 40% of mice developed islet hyperplasia and tumors by their 9th month of age 
[79]. The authors observed gradual steps of tumorigenesis, starting in hyperplasic islets, 
followed by focal atypia and tumors [79]. Two years later, the same authors reported the 
development of another mouse model of MEN1, in which the deletion of exons 3 to 8 of the 
MEN1 gene was performed using the RIP-Cre/LoxP system, directing a specific deletion in 
β-cells to overcome embryonic lethality in homozygous embryos [81]. At 60 weeks of age, 
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more than 80% of homozygous mice developed multiple pancreatic islet adenomas. 
Hyperplasic islets were also found in these mice, with a consistent pattern of insulin 
expression; they posteriorly developed focal atypia, with abnormally sized and shaped cells, 
culminating in the development of pancreatic islet tumors. The authors related the loss of 
menin in β-cells to the atypical phenotype of islets. Tumorigenesis did not appear until the 
mice were 6 to 12 months old, and the evidence pointed towards the fact that adenoma 
formation probably involved additional somatic events to MEN1 deletion [81]. Bertolino et 
al. followed the same rationale: they began by reporting a mouse model with MEN1 
disruption by homologous recombination [80] and later that year (2003) published the 
results of a model with conditional deletion of the gene in pancreatic β-cells using the RIP-
Cre/Lox system [82]. The first study reported hyperplasia and dysplasia in 65% of the 
population by 8 to 12 months, with 22% of adenomas and 8,7% of carcinomas. As the age 
of the mice progressed, the fraction of adenomas and carcinomas increased, with more 
than 60% of carcinomas found in the group of mice with 19 to 26 months of age. 
Immunohistochemistry staining for insulin showed that the majority of neoplasms were 
insulinomas, but advanced islet carcinomas showed either weak or complete loss of 
expression [80]. The second study published by the authors reported enlarged islets by 2 
months of age, a feature which tended to progress with aging. Insulinomas were found at 6 
months of age, and by 10 months of age all the mice comprising the sample presented 
tumors; the increased frequency of tumors was then associated with aging. After 10 months 
of age, all the transgenic mice developed advanced insulinomas (carcinomas), which were 
shown to progressively loose insulin-staining. This finding suggested a dedifferentiation 
process during tumor development [82]. The authors reinforced the advantage of a 
conditional knockout approach for monitoring of the whole process of tumorigenesis: 
hyperplasia, dysplasia and adenoma/carcinoma formation. One more study has performed 
the conditional inactivation of MEN1 in β-cells using the same system [83]. Biondi et al. also 
reported prominent hyperplasia of the pancreatic islets at 12 months of age, which were 
positively stained for insulin. There was an additional development of islet cell tumors in 7 
animals of the tumor sample [83]. In 2009, another mouse model was developed for 
mimicking pancreatic neuroendocrine tumors, using once more the Cre/LoxP system in 
which Cre expression was driven by a different promoter, the pancreatic and duodenal 
homeobox 1 (Pdx1) [86]. Pdx1 is a regulator of pancreatic organogenesis; initially, it is 
expressed in all pancreatic progenitor cells, but postnatally it is only present in β-cells. The 
exocrine and glandular components of the pancreas were observed with a normal pattern, 
while the endocrine fraction was reported as enlarged and hyperplasic as early as 5 months 
of age[86]. These mice exhibited a progression to insulinoma by the age of 10 to 12 months, 
while exocrine cells remained phenotypically normal [86].  
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All the data obtained from these mouse models and others (with target deletions in 
α-cells, for example [75, 77, 84, 85]) were reviewed by Babu et al. (2013). They established 
a multistage pathogenesis for PNETs: the 1st stage is hyperplasia of the pancreatic islets, 
followed by dysplasia/atypia and culminating in the generation of neuroendocrine tumors 
[74].  
In our study population, besides the prominent mononuclear infiltrates in both 
exocrine and endocrine tissues, hyperplasia of the pancreatic islets was one of the main 
findings as consistently addressed before. The endocrine portion is severely increased, and 
while this could be explained by use of the RIP-Cre transgene [109], it appears that this is 
not the case. Enlarged islets of RIP-Cre mice loose β-cells mass, and this is not observed 
in our population; on the contrary, the strong and coherent insulin staining pattern proves 
the proliferation of these cells, as illustrated in figure 19 (A and C). Such results are 
compatible with the ones found for some of the previously reported PNET mouse models 
[81, 83]. These islets are also found to frequently coalesce with one another (figure 19); 
many islets enter a stage of coalescence, in which adjacent islets form even larger, 
irregularly shaped ones. This is thought to be a prior stage to islet adenomas and PNETs. 
This finding has been reported as a previous step in adenoma formation in a mouse model 
of transgenic expression of thymidylate synthase (an essential enzyme for DNA synthesis) 
[110].  
 It is of interest to characterize the expression of ATRX in such hyperplasic and 
irregular islets in the future to try to establish a possible causal relationship between its loss 
and the onset of islet hyper/dysplasia, as it has been done for MEN1 models that lost 
expression of menin in their endocrine portions.  
In this study, 20 pancreatic tumors were found in 161 studied animals (12.4%); they 
were found in both the control and flox groups (5 controls, 12 heterozygous and 3 
homozygous mice; pancreatic tumors are described in table 3). To accurately confirm the 
tumors’ diagnosis, there are postulated immunohistochemical markers defining 
neuroendocrine differentiation that can be used. Chromogranin A and synaptophysin are 
the most used markers. It was observed that all tumors lack expression of both markers 
(figure 23, A and B). They also do not present any expression of insulin, which was 
evaluated since insulinomas arise from β-cells and are the most common type of PNETs 
(this finding is illustrated in figure 23 C). The age of the mice in which these tumors arose 
ranges from 14 to 24 months. The Ki-67 labeling index provided the evidence that we are 
dealing with highly proliferative tumors. If the most recent grading system released by WHO 
for endocrine tumors is to be applied in the found neoplasms, these tumors would be 
categorized mainly as G2 and G3 [21]. Adding to this and according to the histological 
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pattern, the hypothesis of a poorly differentiated neuroendocrine carcinoma phenotype was 
raised. In human cases, the diagnosis of large-cell neuroendocrine carcinoma is confirmed 
by immunohistochemical staining for CgA and SYN, being their extent and intensity usually 
less than in well-differentiated NETs [111]. These markers were not to be expressed in the 
tumors (figure 23, A and B). However, there are additional neuroendocrine markers possible 
to be tested in these samples. CD56 is the cluster differentiation (CD) of neural cell 
adhesion antigen and it has been used (although in a less extent than the previously 
mentioned markers) for the diagnosis of neuroendocrine neoplasms [5, 11, 13, 112], being 
also a possible marker to be applied. Paired Box 8 (PAX8) is a crucial transcription factor 
for the development of the kidneys, thyroid and Mullerian ducts that has recently been also 
related to pancreatic neuroendocrine tumors [113, 114], being considered as a tool for the 
differential diagnosis of NETs [115]. Insulin Gene Enhancer Protein ISL-1 (Islet-1) is a 
transcription factor involved in the embryogenesis of the islets of Langerhans, being 
therefore a sensitive lineage-specific marker for PNETs expressed strongly in the nucleus 
of tumor cells. It is also considered a reliable marker for PNET metastases [116]. Both these 
markers could be potentially used additionally to evaluate the neuroendocrine phenotype of 
the tumors. Pdx1 is a transcription factor essential for pancreatic development and β-cell 
maturation, being expressed in pancreatic cell progenitors and immature cells of endocrine 
lineage that has been associated with not only PNETs but other precursor lesions and 
neoplasms of the pancreas [117]. Given its presence in immature pancreatic cells, it would 
be a useful marker to confirm the hypothesis of a poorly differentiated phenotype for the 
tumors of our sample.  
In 2013, Hunter et al. described a mouse model of pancreatic neuroendocrine 
tumorigenesis in which while the majority of tumors were well-differentiated insulinomas, a 
subset of tumors were identified and characterized as poorly differentiated invasive 
carcinomas (PDICs) [118]. Similarly to what happens in the tumors of our study sample, the 
H&E staining provided a possible PNET phenotype with highly proliferative indexes. The 
immunohistochemical characterization, however, revealed that these neoplasms had 
completely lost expression of CgA, while maintaining a subtle heterogeneous expression of 
SYN. This class of tumors was also reported to lose staining of insulin (as observed in other 
PNET mouse models in which carcinomas developed [80, 82]) and markers of β-cell 
differentiation, such as Pdx1. Thus, to achieve confirmation of the apparent 
dedifferentiation, the authors evaluated the expression of inhibitor of DNA binding 1 (Id1) in 
PDICs. Id1 is an inhibitor of DNA binding proteins that has been shown to inhibit 
differentiation, stimulate proliferation and to be expressed in cancer stem cells [119]. The 
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majority of PDIC cells were found to exhibit a specific nuclear staining pattern, proving the 
poorly differentiated phenotype of the neoplasms [118]. 
If a neuroendocrine phenotype is not proved by immunohistochemistry staining for 
any of these markers, to achieve the diagnosis of tumors a panel of markers must be 
followed, bearing in mind that pancreatic neoplasms arise from different backgrounds [120, 
121]. Pancreatic ductal adenocarcinomas represent about 90% of all malignant pancreatic 
tumors [120]. Immunohistochemistry staining for cytokeratin AE1/AE3 will allow the 
confirmation or exclusion of an epithelial nature of the tumors [28]. Another possible marker 
to ascertain an epithelial origin is the Epithelial Membrane Antigen (EMA) which is highly 
expressed in most adenocarcinomas [122]. If the tumors have a mesenchymal origin, 
immunohistochemistry staining for vimentin (an intermediate filament of mesenchymal 
tissue) will confirm this phenotype. Specifically, among the group of non-epithelial tumors, 
pancreatic lymphoma arose as a proposed diagnosis. A valuable marker to rule out or 
confirm this hypothesis would be the Leukocytic Common Antigen (LCA or CD45), which is 
a membrane glycoprotein restricted to leukocytes that allows the distinction between 
hematopoietic and non-hematopoietic neoplasms[123]. In order to identify the lineage of 
these tumors we will perform a battery of tests that will eventually shed some light on its 
origin. 
We have also hypothesized that hyperplasic and irregular islets could be an initial 
step in tumorigenesis in this model as they are in many others of PNETs [74], however, it 
is precocious to establish a conclusion and further studies are required to associate such 
with ATRX loss, since both RIP-Cre controls and ATRX floxed mice developed pancreatic 
tumors, although the second group presented a higher prevalence (table 3). The tumors 
were found in animals with approximately 16 to 24 months; if these tumors are proven to 
have a poorly differentiated neuroendocrine phenotype, the advanced age is a strong 
contributor to this evolution, as previously reported [80, 82].  
In PNETs, the loss of either ATRX or DAXX has been correlated with the ALT 
phenotype, as previously stated [38, 40-42]. In the context of ALT activation, telomere-
specific FISH allows the detection of ultrabright telomere FISH signals, which constitute 
hallmarks of the pathway due to the unbalanced telomere length as a consequence of a 
homologous recombination process. The optimization of a protocol of telomere-specific 
FISH for FFPE tissues has been performed; the optimization also included the combination 
of tel-FISH with immunofluorescence staining for insulin, in order to co-localize telomeres 
in the nuclei of β-cells. We plan to combine the protocol of tel-FISH with immunostaining for 
PML-bodies, searching for the presence of ALT-associated PML nuclear bodies, the so-
called APBs, and apply it to our tumor sample to investigate a possible activation of this 
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alternative mechanism of cell immortalization[73]. ALT positivity has been related to 
aggressive clinical behavior, advanced disease and poor survival in human PNET patients 
[38, 42]. In case the alternative lengthening of telomeres is found in this tumor subset, it will 
be more evidence of an aggressive phenotype. Understanding the complexity of this model 
requires also that all stages must be verified in order to not exclude pivotal steps that could 
lead to misinformation.  
Cre recombinase was found to be expressed specifically in the nucleus of pancreatic 
β-cells, as expected (illustrated in figure 24). Magnuson and Osipovich reported the protein 
to be expressed in more than 80% of these cells from a collection of data from different 
studies [89]. We observed that despite some islets express this percentage or more, others 
present a much lower percentage of Cre expression, a pattern that varies between islets of 
the same animal. This variability needs now to be extrapolated to a higher number of 
samples to fully understand the average of Cre expression in the population. By crossing 
Rip-Cre+/- mice with mice that have loxP sites flanking exon 18 of ATRX, if Cre recombinase 
is expressed in the offspring’s β-cells, it is expected to recognize these sites and excise the 
exon, disrupting the gene. To confirm this disruption, the protein’s expression needed to be 
characterized in the pancreatic tissue: as expected, control mice maintain the expression 
of ATRX, as well as heterozygous mice, which is expected since the remaining wild-type 
allele retains its original features and allows the production of the protein. Our next step will 
involve the determination of the physical excision of the exon 18 of ATRX by cDNA (from 
RNA) sequencing. Female homozygous mice (ATRXFLOX/FLOX) maintained their expression 
of ATRX in pancreatic islets; however, the number of expressing cells is lower when 
compared to control or heterozygous mice (as shown in figure 25). The RIP-Cre strain is 
reported to achieve recombination in more than 85% of β-cells based on results from 
several laboratories [102], which would mean a major loss of ATRX in the targeted cells. 
However, as previously stated, with the excision of exon 18, an isoform of the protein 
(ATRXt) may be produced [46-48]. The characterization of the protein’s loss needs to be 
performed in a full extent in this study sample, for us to confirm the recombination efficiency 
reported for the system, regarding the fact that if the protein is present in homozygous mice 
it may be the expression of ATRX’s isoform without the SNF2 domain. Beyond that, the 
easiest answer would be that the expression of ATRX in both heterozygous and 
homozygous females is also probably due its production in other pancreatic islet cell types. 
Thus, to ascertain if ATRX is being expressed in α-cells, for example, a double staining 
immunohistochemistry/immunofluorescence protocol for ATRX and glucagon is warranted. 
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6. CONCLUSIONS AND FUTURE PERSPECTIVES 
 
The ATRX conditional knockout mouse has proven to be a challenging animal 
model.  
The main unexpected histological finding was a prominent spontaneous 
inflammation in both the exocrine and endocrine tissues, previously not found, or 
unreported, either for the RIP-Cre strain or any mouse model of pancreatic neuroendocrine 
tumorigenesis. The cause of these infiltrations and their cellular characterization will now 
need to be further investigated. Islet hyperplasia was highly incident among the study 
sample. RIP-Cre mice have been reported to develop enlarged islets that loose β-cell mass 
which is not observed in the subjects of our study sample that maintain a strong expression 
of insulin-producing cells throughout the hyperplasic islets, once more reflecting the 
uniqueness of this model. 
Approximately 12% of mice comprising the cohort developed pancreatic tumors. 
The neoplasms were highly proliferative and lack immunohistochemistry staining for the 
conventional neuroendocrine markers of differentiation. The hypothesis of a poorly 
differentiated neuroendocrine phenotype will have to be tested using markers of 
dedifferentiation. If the neuroendocrine origin is proven absent, a panel of markers must be 
adopted to reach a final diagnosis for the original cell lineage. Additionally, to all these 
findings, once a better understanding of the primary tumor is achieved we will be able to 
focus on distant disease. It would be expectable that such a highly aggressive tumor would 
have distant metastasis, which is found in our model. For a sake of simplicity, metastasis 
were excluded from this initial evaluation. Tumours and metastasis will have to be 
characterized regarding their ALT status given the reported association between ATRX loss 
and ALT activation in human cancers.  
Cre recombinase and ATRX expression need to be analysed in the total population 
to provide the percentage of achieved recombination provided by the Cre-LoxP system. 
Extensive exocrine and endocrine infiltrations, islet hyperplasia and pancreatic tumors were 
observed in both controls and flox mice, without significant differences between groups. 
Age appears as the key factor affecting the progression of these pathological findings. Since 
the stratification by age demonstrated to present major differences, the animals will be 
followed and euthanized in shorter and stipulated time periods, so that the hyperplasia 
onset, possible dysplasia and consequent adenoma and PNET formation may be tracked 
and all stages of pathogenesis are observed.   
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It is known that the creation of a new model of disease is labor intensive. Although 
in theory the conditional knockout of ATRX in the β-cells seemed a breeze, in practical 
terms, it was revealed that this model presents a high complexity. And these, as they may 
seem complicating factors, or “bad news”, are indeed fascinating findings that confirm once 
more that the tumorigenic initiation and/or progression is a multifactorial process in cancer. 
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APPENDIX I 
 
 
Figure 28. Ki-67 labeling index obtained with ImmunoRatio. 
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APPENDIX II 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Endocrine fraction measurement using ImageJ, showing islet circumvention 
(A) and the color threshold tool that selects all pancreatic tissue excluding interlobular 
areas (B). 
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APPENDIX III 
 
Table 3. Adapted score of pancreatic lesions evaluation 
 
  
Scoring criteria 
Edema 0 absent 
1 interlobular edema alone 
2 interlobular and scarce intralobular edema 
3 interlobular and moderate intralobular edema 
4 interlobular and severe intralobular edema 
Leukocytic 
infiltration 
0 absent 
1 scarce perivascular/periductal infiltration alone 
2 scarce perivascular/periductal infiltration and scarce diffuse infiltration 
3 moderate perivascular/periductal and absent to scarce diffuse infiltration 
4 moderate perivascular/periductal and diffuse infiltration 
5 abundant diffuse infiltration 
Insulitis 0 absent 
1 infiltrates in small foci at the islet periphery 
2 infiltrates surrounding the islets (peri-insulitis) 
3 intraislet infiltration < 50% of the islet 
4 extensive infiltration, ≥ 50% of the islet 
Vacuolization 0 absent 
1 < 25% of acinar cells involved 
2 25-50% of acinar cells involved 
3 > 50% of acinar cells involved 
Hemorrhagia 0 absent 
1 1-2 hemorrhagic foci per slide 
2 3-5 hemorrhagic foci per slide 
3 > 5 hemorrhagic foci per slide 
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Figure 30. Illustrative grading of edema (Scores 1 to 4). 
Score 1 Score 2 
Score 3 Score 4 
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